






























Cannabis	 has	 been	 used	 to	 treat	 many	 diseases	 for	 centuries.	 Recent	 medical	 interest	 has	
focused	on	the	potential	of	cannabinoids	to	treat	diseases	such	as	multiple	sclerosis,	epilepsy,	
and	 cancer	 where	 research	 has	 focused	 on	 investigating	 cannabidiol	 (CBD).	 However,	 other	
cannabinoids,	such	as	cannabigerol	(CBG),	remain	poorly	characterised	and	are	being	explored	
as	 potential	 treatments.	 The	 molecular	 mechanisms	 by	 which	 cannabinoids	 treat	 diseases	
remain	 unclear,	 despite	 suggested	 targets	 including	 adenosine,	 mTOR,	 transient	 receptor	








activity	 in	 wild	 type	 cells.	 Elevated	 expression	 of	 IPMK	 increased	 mTORC1	 activity,	 but	
surprisingly,	 subsequent	 treatment	 with	 both	 CBG	 and	 CBD	 reduced	 mTORC1	 activity,	
suggesting	 that	 cannabinoids	 functioned	 as	 pro-homeostatic	 regulators	 of	 mTORC1	 activity	
through	 IPMK.	Translating	these	results	 into	mouse	embryonic	 fibroblasts,	CBG	and	CBD	also	
increased	mTORC1	activity	in	an	IPMK-dependent	manner.	Finally,	in	primary	human	peripheral	
blood	mononuclear	cells	(PBMCs)	derived	from	healthy	volunteers	CBG	and	CBD	also	increased	
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with	 PBMC-based	 experiments,	 Lisa	 Costelloe,	 Dr	 Eric	 Downer	 and	 John-Mark	 Fitzpatrick	 at	
Trinity	College	Dublin.	Thank	you	for	adenosine	experiments,	Dr	Nicola	Gray,	Martina	Cherubin	
and	Dr	Mark	Dallas	at	the	University	of	Reading.	Thank	you	for	allowing	me	to	come	to	the	lab	





my	 degree	 and	 I	 am	 very	 grateful	 to	 both.	 Devdutt	 Sharma,	 Christopher	 Perry,	 Marco	
Cocorocchio,	Kate	Augustin	and	Lizzy	Kelly	welcomed	me	into	the	lab	and	gave	me	the	start	I	
needed	 to	 pursue	 this	 project.	 Fraser	 Morgan	 provided	 me	 with	 a	 year	 of	 motivation	 and	
enjoyment.	Rob	Prouse	was	an	essential	friend	and	colleague.	Thank	you,	Erwann	Pain,	for	help	
with	 adenosine-related	 experiments	 in	 D.	 discoideum.	 George	 Heslop-Harrison,	 Anthony	
Goddard,	Sonia	Shinhmar	and	Maryam	Nagib	have	all	been	great	additions	to	the	lab	and	helped	
me	with	the	final	push	to	the	end	of	my	degree.	Other	colleagues	have	also	helped	me	during	



















from	1700	BC	 to	 the	modern	day	has	been	suggested	as	a	 remedy	 for	a	variety	of	ailments,	
including	senility	(Russo,	2007),	glaucoma	(Colasanti,	1990),	inflammation	(Osbaldeston,	2000),	
pain	 relief	 (Lozano,	 2001),	 infection	 (Russo,	 2007),	 anxiety	 (Devinsky	 et	 al.,	 2014),	 diarrhoea	
(Russo,	2007),	anorexia	(McCoy	et	al.,	2018),	consumption	(Butrica,	2002),	and	convulsion	(for	




Therapeutic	 cannabinoids	 are	 currently	 prescribed	 as	 legal	 and	 controlled	 treatments	 for	
anorexia	in	patients	with	AIDs	or	undergoing	cancer	treatment	(Calhoun	et	al.,	1998),	multiple	
sclerosis	(Etges	et	al.,	2016),	and	epilepsy	(Gray	et	al.,	2019).	Over	€500	million	has	been	invested	






























under-researched	 compared	 to	 CBD	 and	 THC.	 This	 search	was	 performed	 on	 Pubmed	 using	




























Study Form	of	C.	sativa THC	% CBD	% CBG	%
Potter	et	al.,	2008 Powder 95.83 0.42 3.75
Potter	et	al.,	2008 Resin 44.25 52.13 3.63
Potter	et	al.,	2008 Herbal 87.35 4.08 8.57
Potter	et	al.,	2008 Sinsemilla 96.48 0.69 2.83
Vandrey et	al.,	2015 Medical 91.53 3.39 5.08
Swift	et	al.,	2013 Marijuana	police	seizures,	USA 89.28 6.13 4.59
Swift	et	al.,	2013 Sinsemilla	police	seizures,	USA 95.04 1.65 3.31
Swift	et	al.,	2013 Marijuana	police	seizures,	UK 87.50 4.17 8.33
Swift	et	al.,	2013 Sinsemilla	police	seizures,	UK 96.55 0.69 2.76
Swift	et	al.,	2013 Indoor	grown	police	seizures,	Australia	(NSW) 95.75 0.70 3.55
Swift	et	al.,	2013 Outdoor	grown	police	seizures,	Australia	(NSW) 86.81 0.17 13.02
Valdeolivas et	al.,	2012 Huntington’s	disease	model	treatment	(THC-based) 98.31 0.42 1.27
Valdeolivas et	al.,	2012 Huntington’s	disease	model	treatment	(CBD-based) 3.40 94.98 1.62



















occurring	more	 than	 24	 hours	 apart	 (Fisher	 et	 al.,	 2014).	 Epilepsy	 affects	 65	million	 people	













and	 altering	 consciousness.	 During	 epilepsy,	 neuronal	 loss	 often	 occurs	 in	 the	 hippocampus	
(Kälviäinen	 et	 al.,	 1998).	 Neuronal	 loss	 is	 often	 accompanied	 by	 gliosis	 (proliferation	 or	






net	 negative	 transmembrane	 potential	 (Hill	 et	 al.,	 2014).	 If	 this	 balance	 is	 altered,	 then	
depolarisation	of	the	membrane	can	occur	and	transmitted	through	the	neuron	(Kaplan	et	al.,	
2017).	This	 leads	to	neurotransmitter	release	and	further	action	potentials	 (Fišar,	2009).	One	









and	 Ward,	 1974).	 Therefore	 seizures	 can	 result	 in	 a	 vicious	 cycle	 where	 a	 transmembrane	
potential	 perturbation	 can	 create	 more	 and	 more	 perturbations	 (Scharfman,	 2007).	
Furthermore,	abnormalities	in	the	sodium	channels	could	result	in	a	decreased	threshold	for	an	
action	 potential,	 this	 is	 the	 case	 in	 generalised	 epilepsy	with	 febrile	 seizures	 (Meisler	 et	 al.,	
2001).	
Another	factor	that	impacts	the	spread	and	severity	of	seizures	is	synaptic	transmission.	In	the	
synapse,	 an	 action	 potential	 is	 carried	 forward	 to	 another	 neuron	 through	 the	 release	 of	
neurotransmitters,	such	as	γ-aminobutyric	acid	(GABA)	and	glutamate	(Kullmann	and	Semyanov,	











direct	 intercellular	 channels,	 may	 also	 aid	 in	 synchronisation	 of	 neuronal	 action	 potentials	
(Traub	et	al.,	2004).	
One	 major	 contributor	 to	 the	 development	 of	 epilepsy	 is	 calcium	 ion	 accumulation	 in	
hippocampal	neurons	(Nazıroğlu	et	al.,	2012).	Transient	receptor	potential	vanilloid	1	(TRPV1)	is	





al.,	 2010).	 This	 finding	 led	 to	 the	 exploration	 of	 TRPV1	 as	 a	 potential	 treatment	 target	 for	
epilepsy.	 In	 temporal	 lobe	 epilepsy	 there	 is	 an	 increased	 expression	 of	 TRPV1	 in	 the	
hippocampus	(Sun	et	al.,	2013).	








al.,	 2018).	 CB2	 receptors	 are	 expressed	 at	 a	 lower	 level	 in	 the	 CNS	 and	 is	 more	 present	 in	
microglia,	vasculature,	immune	cells	and	some	neurons,	such	as	dopaminergic	neurons	in	the	
ventral	 tegmental	 area	 and	 hippocampal	 CA3	 neuronal	 cells	 (Arévalo-Martín	 et	 al.,	 2003;	
O’Sullivan	et	al.,	2009;	Chen	et	al.,	2017).	GPR55	are	located	primarily	in	the	brain	and	peripheral	
nervous	system	(PNS),	GPR55	activation	in	the	PNS	an	result	in	increased	intracellular	calcium	




action	 potential	 and	 reduce	 release	 of	 glutamate	 across	 the	 synapse	 (Figure	 1.2)	 (Busquets-
Garcia	 et	 al.,	 2018).	 Therefore,	 CB1	 receptor	 activation	 by	 endocannabinoids	 produces	







anticonvulsant,	 released	 after	 a	 seizure	 as	 a	 terminator	 and	 works	 through	 the	 adenosine	
receptor	 1	 protein	 (During	 and	 Spencer,	 1992;	 Lado	 and	Moshé,	 2008).	 The	 anti-convulsant	
effect	 of	 adenosine	 occurs	 through	 the	 upregulation	 of	 presynaptic	 neuron	 inhibition,	
preventing	 runaway	excitement	 in	 feed-forward	synaptic	circuits	 (Huber	et	al.,	2001;	Boison,	
2012),	 thus	adenosine	 stabilises	 the	post-synaptic	membrane	potential.	Adenosine	 therefore	
acts	 to	 stop	 the	 spread	 of	 a	 seizure	 and	 elevated	 extracellular	 adenosine	 levels	 can	 reduce	
seizure	frequency	(Li	et	al.,	2008;	Fukuda	et	al.,	2010).	A	reduction	of	extracellular	adenosine	
can	 be	 caused	 by	 over-expression	 of	 adenosine	 kinase,	 which	 phosphorylates	 adenosine	 to	
produce	 adenosine	monophosphate	 (AMP)	 (Lovatt	 et	 al.,	 2012).	 An	 increased	 expression	 of	
adenosine	kinase	(ADK),	can	result	in	a	much	quicker	progression	of	the	disease,	as	it	reduces	









Furthermore,	 ADK	overexpression	 is	 linked	 to	 epileptogenesis.	 ADK	 is	 primarily	 expressed	 in	







































Figure	 1.2:	 Cannabinoid	 receptors.	 Endocannabinoids	 control	 neuronal	 transmission	 and	 action	
potentials.	An	action	potential	causes	the	release	of	glutamate	across	the	synapse	from	the	presynaptic	
neuron.	 Glutamate	 stimulates	 an	 action	 potential	 in	 the	 postsynaptic	 neuron	 through	 glutamate	
receptors	and	sodium	ion	channels.	However,	this	also	creates	a	feedback	in	which	endocannabinoids	
are	produced	from	fatty	acids	in	the	postsynaptic	neuron.	These	then	release	into	the	synapse	and	inhibit	










(Li	 et	 al.,	 2012).	 In	 addition,	 this	 increases	 the	 abundance	 of	 methyl	 groups	 in	 the	
transmethylation	pathway,	 resulting	 in	 increased	DNA	methylation	 (Williams-Karnesky	et	 al.,	
2013).	DNA	methylation	 has	 an	 inhibitory	 effect	 on	 gene	 expression,	 reducing	 expression	of	
nearby	 genes	 and	 increasing	 the	 likelihood	 of	 further	 inhibitory	 epigenetic	 changes	 such	 as	
histone	deacetylation	(Rountree	et	al.,	2000).	In	general,	DNA	methylation	is	a	key	regulator	of	
gene	control	and	is	often	cell-type	specific	(Moore	et	al.,	2013).	DNA	methylation	is	also	a	key	
regulator	of	development	 (Pucci	et	al.,	 2013),	 cell	 fate	 (Kredich	and	Martin,	1977),	 cell	 cycle	




and	network	activity	 in	hippocampal	slices	 (Levenson	et	al.,	2006).	A	global	 increase	 in	DNA-
methyltransferase	 activity	 and	DNA	methylation	was	 correlated	with	 spontaneous	 recurrent	
seizures	 in	 mice	 and	 reversed	 by	 adenosine	 augmentation	 (Williams-Karnesky	 et	 al.,	 2013).	




target	 of	 rapamycin	 (mTOR)	 pathway.	 Mutations	 in	 the	 tuberous	 sclerosis	 complex	 (TSC)	
proteins	 or	 phosphatase	 and	 tensin	 homolog	 (PTEN)	 protein	 lead	 to	 abnormal	 neuronal	
proliferation	and	growth	in	animal	models	(LaSarge	and	Danzer,	2014).	Humans	with	mutations	
in	either	of	the	two	TSC	proteins	develop	cortical	tubers	found	in	the	cortex	or	subcortical	white	
matter	 and	 lead	 to	 the	 development	 of	 refractory	 seizures,	 surgical	 removal	 of	which	 often	
reduces	 seizure	 occurrence	 (Weiner	 et	 al.,	 2006).	 These	 tubers	 promote	 hyperexcitability	 of	
neurons	and	seizures	(Mühlebner	et	al.,	2016).	Dysregulation	of	mTOR	signalling		can	also	lead	
to	changes	in	gene	and	protein	expression	that	increase	the	likelihood	of	neuronal	excitability	
and	 seizures	 (Boer	 et	 al.,	 2010).	 In	Hemimegaloencephaly	 there	 is	 an	 overreaction	 of	mTOR	
signalling	in	some	neural	tissue,	potentially	caused	by	somatic	mutations	in	genes	involved	in	








(Cook	 et	 al.,	 2013).	 One	 target	 for	 AEDs	 is	 voltage-gated	 sodium	 channels.	 These	 channels	
control	 the	 rising	 phase	 of	 neuronal	 action	 potentials.	 AEDs	 that	 target	 these	 channels	 are	
oxcarbazepine,	 zonisamide,	 phenytoin,	 carbamazepine,	 lamotrigine	 and	 possibly	 valproate	
(Yaari	et	al.,	1986;	Schmutz	et	al.,	1994;	Ambrósio	et	al.,	2002;	Leppik,	2004).	The	other	main	
mechanism	 of	 action	 of	 AEDs	 is	 to	 act	 on	 γ-aminobutyric	 acid	 (GABA)	 transmission	 (Davies,	









as	 potential	 therapeutics	 for	 epilepsy	 has	 increased,	 in	 addition,	 self-medicating	 epilepsy	
patients	have	begun	to	use	Cannabis	to	alleviate	symptoms	(Szaflarski	and	Bebin,	2014).	Some	
studies	 have	 found	 that	 Cannabis	 use	 can	 make	 epilepsy	 symptoms	 worse	 (Gordon	 and	




CBD,	a	non-psychoactive	constituent	of	Cannabis	decreases	 frequency	of	 seizures	 in	patients	
suffering	 from	 epilepsy	 that	 AEDs	 could	 not	 control	 (Devinsky,	 Patel,	 et	 al.,	 2018).	 Potential	




















CBD	 has	 therefore	 been	 found	 to	 have	 anti-seizure	 effects	 in	 animal	 models	 of	 epilepsy,	
providing	a	potential	treatment	for	the	disease.	
As	certain	cannabinoids	 (in	particular	CBD)	were	 found	 to	be	safe	and	efficacious	 in	 treating	
epilepsy	in	animal	models,	clinical	trials	examined	how	effective	the	treatment	was	in	humans.	








(Halford	 et	 al.,	 2018).	 In	 addition,	 88	 %	 of	 caregivers	 reported	 an	 improvement	 in	 overall	








(McCoy	 et	 al.,	 2018).	 This	 efficacy	 has	 led	 to	 Epidiolex®	 prescription	 legalisation	 in	 many	






sclerosis.	 This	 is	 a	 chronic,	 inflammatory	 and	 neurodegenerative	 disease	 which	 begins	 with	
demyelination	of	neurons	and	 leads	 to	variable	axonal	and	neuronal	 injury	 (Wingerchuk	and	
Carter,	 2014).	 Multiple	 sclerosis	 (MS)	 causes	 disability	 in	 young	 adults	 and	 reduces	 life	
expectancy	 by	 5	 to	 10	 years	 (Riccio	 and	 Rossano,	 2015;	 NHS,	 2018).	 The	 disease	 causes	 an	
interruption	of	myelin	tracts	in	the	CNS,	initially	causing	weakness,	diminished	dexterity,	visual	






sclerosis,	 some	 regions	 are	 more	 commonly	 damaged	 than	 others.	 Where	 veins	 become	
inflamed	in	the	brain,	due	to	increased	inflammatory	cytokine	release	and	immune	response,	







MS	 is	 characterised	 by	 inflammation	 at	 the	 blood-brain	 barrier	 due	 to	 the	 auto-reaction	 of	
multiple	immune	cells	(T	cells,	B	lymphocytes,	macrophages	and	microglial	cells)	against	brain	
and	spinal	cord	white	matter	(Rajesh	et	al.,	2007).	This	causes	one	or	two	relapses	annually	into	








(Bar-Or	et	al.,	2003).	 In	 immune	cells,	mTORC1	activity	 is	often	at	a	much	higher	rate	than	in	
27	
	
healthy	 individuals,	 which	 contributes	 to	 the	 overproduction	 of	 pro-inflammatory	 cytokines	











response	and	attack	 to	 that	protein	 (Oksenberg	and	Barcellos,	 2005).	However,	 exact	 causal	
mutations	are	not	yet	understood.		
There	 are	multiple	 disease-modifying	 therapies	 (DMTs)	 currently	 available	 that	 slow	 disease	
progression	and	relieve	some	symptoms.	One	of	the	main	DMTs	available	as	a	therapeutic	for	
MS	 is	 interferon	 beta	 and	 glatiramer	 acetate.	 The	 exact	 mechanism	 of	 action	 for	 these	
treatments	are	unknown	but	they	reduce	blood	brain	barrier	disruption,	modulate	T-	and	B-cells	
and	 cytokine	 functions	 and	 the	 glatiramer	 acetate	 stimulates	 regulatory	 T	 cells	 (Dhib-Jalbut,	
2002).	These	drugs	reduce	clinical	relapse	rate	by	a	third,	but	have	little	effect	on	progressive	
MS	(Wingerchuk	and	Carter,	2014).	A	general	immunosuppression	drug	can	be	used	for	rapidly	








nervous	 system	 infection	 by	 the	 John	 Cunningham	 virus	 (Kleinschmidt-DeMasters	 and	 Tyler,	
2005).	This	can	lead	to	multifocal	leukoencephalopathy	and	death	or	irreversible	neurological	










patients	with	 heart	 disease	 (Cohen	 et	 al.,	 2010).	 Another	 orally	 taken	DMT	 is	 terifunomide.	









cell	 count	 is	usually	observed	with	 terifunomide	treatment,	and	 lymphopenia	can	develop	 in	
patients	 on	 this	 drug,	 therefore	 blood	 cell	 count	 is	 monitored	 for	 patients	 who	 take	 this	
(Berkovich	 and	 Weiner,	 2015).	 In	 addition,	 infection	 risk	 could	 by	 increased	 by	 taking	 this	
treatment.	There	are	also	MS	DMTs	that	are	emerging	in	recent	years.		
Alemtuzumab	 is	 a	 new	 drug	 that	 has	 a	 lower	 relapse	 rate	 than	 interferon	 treatment.	
Alemtuzumab	 is	a	humanised	anti-CD52	monoclonal	antibody	(Coles	et	al.,	2012).	 It	depletes	











There	 has	 also	 been	 a	 suggestion	 that	 the	 endocannabinoid	 system	may	 be	 involved	 in	MS	
disease	development	and	a	potential	target	for	treatment.	In	many	experimental	models	of	MS	










develop	 neurodegeneration	 (Pryce	 et	 al.,	 2003;	 Chiurchiù	 et	 al.,	 2018),	 while	 CB2	 receptor	
deletion	in	T	cells	from	MS	model	mice	led	to	increased	T	cell	proliferation,	reduced	apoptosis,	
elevated	inflammatory	cytokine	release	and	worsened	symptoms	(Maresz	et	al.,	2007).	THC	was	
found	 to	 limit	 inflammation,	 disease	 development,	 CNS	 infiltration	 and	microglial	 activation	
while	promoting	myelin	repair,	potentially	through	THC	activation	of	CB1	receptors	(Pryce	et	al.,	





time	 (Kornek,	 2000).	 A	 study	 in	 2017	 on	mouse	 experimental	 autoimmune	 echepalomyelitis	
(EAE)	cells	found	that	the	disease	model	had	a	lower	activation	of	the	PI3K/Akt/mTOR	pathway	
(Giacoppo	et	al.,	2017).	The	phosphorylation	of	these	proteins	found	lower	levels	in	the	disease	
model,	 but	 when	 treated	 with	 CBD	 there	 was	 an	 increase	 in	 phosphorylation.	 Non-
phosphorylated	PI3K/Akt/mTOR	proteins	did	not	significantly	change	with	treatment,	meaning	







yet	 to	be	explored,	but	 they	provide	a	potential	 treatment	of	 symptoms	and	potentially	 the	
causes	of	the	disease	with	few	side	effects.		
One	 common	 and	 effective	 animal	 model	 for	 MS	 is	 the	 experimental	 allergic	 autoimmune	





al.,	 2014).	 The	effect	 created	 in	 an	EAE	model	mouse	 is	 very	 similar	 to	 that	which	occurs	 in	
patients	with	MS	(Robinson	et	al.,	2014).	In	EAE	model	mice,	treatment	with	Sativex®	(which	is	
a	 complex	 botanical,	 the	 therapeutic	 effects	 of	 which	 are	 derived	 from	 the	 totality	 of	 the	
product,	and	not	THC/CBD	alone.)was	found	to	reduce	spasticity	by	40	%	and	was	as	effective	

















similar	mixture	 of	 THC	 and	 CBD	was	 found	 to	 decrease	 spasticity	 in	MS	 patients	 as	 add-on	













The	 first	 known	 targets	 of	 cannabinoids	 in	 animals	 were	 cannabinoid	 receptors.	 These	 are	
G-protein-coupled	receptors	that	mediate	the	effect	of	endocannabinoids	in	the	body	(Howlett	
et	 al.,	 2002).	 Cannabinoid	 receptor	 1	 (CB1)	 is	 prominent	 in	 the	 central	 nervous	 system	
(Herkenham	et	al.,	1991)	while	cannabinoid	receptor	2	(CB2)	is	expressed	in	the	brain,	testes	and	
spleen	 (Liu	 et	 al.,	 2009).	 In	 the	 absence	of	 exogenous	 cannabinoids,	 these	proteins	 regulate	
synaptic	transmission	(Paradisi	et	al.,	2008).	However,	THC	activates	these	receptors,	while	CBD	
acts	 as	 an	 indirect	 antagonist	 (Laprairie	 et	 al.,	 2015).	One	 study	 found	 that	 pharmacological	
cannabinoid	receptor	antagonism	ameliorated	tremor	and	spasticity	in	MS	model	mice	(Baker	
et	 al.,	 2000).	 Another	 study	 found	 that	 expression	 of	 CB1	 in	 neurons	 was	 required	 for	
cannabinoid-mediated	 suppression	 of	MS-like	 symptoms	 in	 an	 EAE	model	mouse,	while	 CB2	
expression	 on	 T	 cells	 was	 required	 for	 a	 cannabinoid-mediated	 reduction	 in	 immune	 cell-













transmission	 or	 an	 increased	 threshold	 (Devinsky	 et	 al.,	 2014).	 Research	 on	 the	 effects	 of	
cannabinoids	 on	 GPR55,	 therefore,	 remains	 unclear,	 but	 both	 CBD	 and	 THC	 may	 have	
antagonistic	effects	on	this	protein.	
1.2.2	Cannabinoid	interaction	with	transient	receptor	potential	channels	
Another	 protein	 family	 that	 are	 known	 to	 be	 biochemical	 targets	 of	 cannabinoids	 are	 the	
transient	receptor	potential	(TRP)	channels.	These	are	a	family	of	membrane	proteins	involved	







Petrocellis	 et	 al.,	 2011),	 and	both	CBD	and	CBG	 stimulate	 TRPV1	and	TRPV2	and	 antagonise	
TRPM8	(De	Petrocellis	et	al.,	2011).	CBD	was	found	to	reduce	seizure	sensitization	from	repeated	
pentylenetetrazol	 (PTZ)	 treatment	 in	 a	 TRPV1-dependent	 manner	 (Vilela	 et	 al.,	 2017).	
Furthermore,	in	another	mouse	model	of	epilepsy,	CBD	increased	the	seizure	threshold	in	wild	
type	 mice,	 while	 this	 effect	 was	 not	 observed	 in	 TRPV1-ablated	 mice,	 except	 at	 high	
concentrations	of	CBD	(Gray	et	al.,	2019).	This	would	reduce	extracellular	calcium	release	and	














adenosylhomocysteine	 which	 is	 converted	 into	 adenosine	 and	 homocysteine	 (Figure	 1.3).	
Therefore,	elevated	intracellular	adenosine	results	in	decreased	DNA	methylation,	and	likewise,	
decreased	 intracellular	 adenosine	 results	 in	 increased	 DNA	 methylation.	 The	 links	 between	
adenosine	 and	 DNA	 methylation	 are	 important	 to	 the	 progression	 of	 epilepsy,	 known	 as	
epileptogenesis.	 This	 is	 because	 elevated	 DNA	 methylation	 results	 in	 epileptogenesis,	 and	
adenosine	 treatment	 inhibits	 epileptogenesis	 through	 reducing	 DNA	 methylation	 (Williams-
Karnesky	et	al.,	2013).		
Previous	studies	have	indicated	that	cannabinoids	may	block	adenosine	uptake.	CBD	has	been	
found	to	 increase	extracellular	adenosine	 in	rat	nucleus	accumbens	 (Mijangos-Moreno	et	al.,	
2014)	 and	 inhibit	 the	 uptake	 of	 adenosine	 into	macrophages	 and	microglia	 by	 inhibition	 of	
33	
	
equilibrative	 nucleoside	 transporter	 1	 (ENT1)	 (Carrier	 et	 al.,	 2006;	 Liou	 et	 al.,	 2008).	 CBD-
dependent	 inhibition	 of	 adenosine	 uptake	 through	 ENT1	 was	 found	 to	 have	 an	 anti-
inflammatory	effect	in	rat	retinal	microglial	cells	and	reduced	diabetes-related	retinal	damage	
in	 this	model	 (Liou	et	 al.,	 2008).	 The	neuroprotective	effect	of	CBD	 treatment	on	hypoxia	 in	
newborn	mice	was	also	found	to	be	dependent	upon	adenosine	signalling,	as	pharmacological	
inhibition	of	an	adenosine	receptor	 (A2A)	 reversed	the	neuroprotective	effects	 (Castillo	et	al.,	
2010).	 CBD	 may,	 therefore,	 act	 to	 reduce	 seizures	 by	 modulating	 adenosine	 transport	 or	
signalling.	The	extent	to	which	cannabinoid	modulation	of	adenosine	transport	could	affect	DNA	




















































transport	adenosine	 into	or	out	of	 the	 cell	down	 concentration	gradients.	 Inside	 the	 cell,	 adenosine	 is	
rapidly	phosphorylated	by	ADK	into	AMP,	which	can	activate	AMPK.	Adenosine	is	a	substrate	and	inhibitor	
of	 S-adenosylhomocysteine	 hydrolase.	 S-adenosylhomocysteine	 is	 an	 inhibitor	 of	 methyltransferases.	
Therefore,	an	elevated	level	of	intracellular	adenosine	rapidly	results	in	inhibition	of	the	methyltransferase	
pathway	and	as	a	result,	decreased	DNA	methylation	(Hermes	et	al.,	2007).	TH-Folate:	tetrahydrofolate;	




















PKB	 itself	 is	 activated	 by	 growth	 factor	 signalling,	 which	 results	 in	 the	 production	 of	
phosphatidylinositol	(3,4,5)-trisphosphate	(PIP3)	by	phosphoinositide	3-kinases	(PI3K),	including	
IPMK	 (Chang	et	al.,	2014;	Herrero-Sánchez	et	al.,	2016).	While	 insulin	 signalling	can	 result	 in	
inhibition	 of	 PKB	 by	 diphosphoinositol	 pentakisphosphate	 (IP7),	 which	 is	 produced	 by	 a	
combination	of	inositol	kinase	proteins	including	IPMK,	inositol	hexakisphosphate	(IP6)	kinase	1	
(IP6K1)	 and	 inositol	 hexakisphosphate	 and	 diphosphoinositol-pentakisphosphate	 kinase	 2	
(PPIP5K2)	(Mackenzie	and	Elliott,	2014;	Kim	et	al.,	2017;	Yousaf	et	al.,	2018).	mTOR	complexes	




Preclinical	 studies	have	 suggested	 that	CBD	upregulates	mTORC1	activity,	 through	PI3K-	 and	





found	 that	 cannabinoids	 reduce	mTORC1	 activity	 in	 certain	models.	 In	 a	 zebrafish	model	 of	
tuberous	sclerosis	complex-associated	epilepsy,	mTORC1	activity	was	found	to	be	constitutively	
elevated,	while	CBD	treatment	both	reduced	seizures	and	mTORC1	activity	in	the	brain	(Serra	et	
al.,	 2019).	 Furthermore,	 in	a	mouse	model	of	breast	 cancer,	CBD	 induced	apoptosis	 through	
downregulation	of	mTORC1	activity	(Sultan	et	al.,	2018).	Together,	these	studies	indicate	that	





































present	 in	 therapeutically	 effective	 C.	 sativa	 extracts.	 In	 one	 study,	 CBG	 was	 found	 to	 be	
effective	as	a	neuroprotectant	in	a	mouse	Huntington’s	disease	model	(Valdeolivas	et	al.,	2015).	
In	addition,	CBG	reduced	reactive	oxygen	species	production	in	colonic	epithelial	cells	and	nitrite	
production	 in	 peritoneal	 macrophages,	 suggesting	 it	 could	 have	 a	 beneficial	 effect	 on	




















Figure	 1.5:	mTORC1	 and	mTORC2	 signalling.	mTORC1	 and	mTORC2	 are	 keystones	 in	 cell	 signalling.	




neuroprotective	effects	 in	 an	 in	 vitro	model	of	neuroinflammation	 (Gugliandolo	et	 al.,	 2018)	















more	 recently	 than	D.	 discoideum	 (Bapteste	 et	 al.,	 2002;	 Eichinger	 et	 al.,	 2005).	However,	 a	
common	 fungal	model	organism,	 yeast,	has	undergone	a	higher	 rate	of	evolutionary	 change	
than	D.	 discoideum,	 meaning	 that	 the	 amoeba	 is	 in	 many	 ways	 genetically	 more	 similar	 to	
animals	than	yeast	(Insall,	2005).	The	genome	of	D.	discoideum	contains	around	12500	genes	


















changes,	 potentially	 indicating	 a	 distinct	 range	 of	 drug	 targets	 in	 pharmacogenetic	 studies	
(Sekine	 et	 al.,	 2018).	 Furthermore,	 pharmacogenetic	 studies	 can	 also	 be	 used	 to	 assess	 the	
toxicity	of	a	 compound,	alongside	any	 inhibitory	effects	 it	may	have	on	growth	 (Perry	et	al.,	
2020).	The	development	of	D.	discoideum	has	been	used	as	a	simple	model	for	the	development	
of	higher	eukaryotes	to	test	the	safety	of	epilepsy	treatment	(Tillner	et	al.,	1998).	More	recently,	




D.	discoideum	has	 also	been	a	useful	 organism	 for	 studying	 cell-cell	 signalling.	 Cyclic	AMP	 is	




signal	 centre,	 up	 the	 gradient	 during	 the	 rising	 phase	 of	 the	 waves,	 resulting	 in	 a	 periodic	
movement	to	the	centre.	Initial	variations	in	cell	density	cause	a	further	increase	in	cell	density	
in	the	densest	areas,	and	this	results	in	a	centre	of	aggregation	(Levine	and	Reynolds,	1991).	D.	
discoideum	 have	 evolved	 to	 begin	 the	 process	 of	 aggregation	 by	 cAMP	 signalling	 upon	







reducing	 the	 extracellular	 concentration	 of	 cAMP	 further,	 allowing	 the	 cycle	 to	 begin	 again	
(Parent	 and	 Devreotes,	 1996).	 These	 findings	 have	 helped	 in	 the	 understanding	 of	 cell-cell	
communication	and	coordination	of	cell	movements	within	a	multicellular	organism	(Singer	et	
al.,	2019).	
Due	 to	 the	 sequencing	 of	 the	D.	 discoideum	 genome	 and	 that	 the	 genome	 is	 haploid,	 this	
organism	has	been	useful	for	carrying	out	pharmacogenetic	studies.	To	this	end,	a	mutagenic	
library	was	created	in	D.	discoideum	by	random	genomic	disruption	through	restriction	enzyme-










process.	Using	D.	discoideum	 the	anti-epileptic	drug	valproic	 acid	 (VPA)	was	 found	 to	 inhibit	
phosphoinositide	 signalling,	 which	 indicated	 that	 VPA	 may	 treat	 epilepsy	 through	
phosphoinositide	 regulation	 (Chang	 et	 al.,	 2012).	 A	 structure-activity	 relationship	 in	 D.	
Figure	1.6:	The	D.	discoideum	life	cycle.	During	the	growth	phase,	D.	discoideum	exists	as	a	free	living	
single	celled	organism.	Red	represents	D.	discoideum	which	have	the	capability	of	a	free	living	lifecycle.	
In	 blue	 are	 cells	 that	 have	 differentiated	 into	 becoming	 future	 stalk	 cells.	 During	 times	 of	 nutrient	

















Lithium	 is	 a	 common	 treatment	 for	 bipolar	 disorder,	 however	 the	mechanism	of	 action	was	
relatively	unknown	(Shaltiel	et	al.,	2004).	Using	D.	discoideum	both	lithium	and	VPA	were	found	
to	 block	 development	 (Williams	 et	 al.,	 2002).	 Screening	 the	mutant	 library	 in	D.	 discoideum	
identified	a	lithium-resistant	mutant	and	an	inactive	prolyl	oligopeptidase	protein	responsible	
for	this	resistance.	An	orthologue	of	this	protein	has	been	linked	to	patients	with	bipolar	disorder	
previously	 (Breen	 et	 al.,	 2004).	 Loss	 of	 prolyl	 oligopeptidase	 was	 found	 to	 elevate	 inositol	
triphosphate	 levels	 (IP3),	which	 appeared	 to	 overcome	 the	 reduction	 of	 IP3	 levels	 caused	 by	





for	 the	 action	 of	 CBD	 were	 identified	 as	 part	 of	 the	 glycine	 cleavage	 system.	 Using	 gas	




Furthermore,	 an	 examination	 of	 the	 molecular	 mechanisms	 of	 caffeine	 found	 that	 caffeine	
inhibits	PI3K	and	mTORC2	activity	in	D.	discoideum,	which	in	turn	inhibits	the	synthesis	of	cyclic	
adenosine	monophosphate	(cAMP)	(Tariqul	Islam	et	al.,	2019),	confirming	a	mechanism	found	




methyltransferase	 (DNMA)	 found	 to	 be	 responsible	 for	 the	 silencing	 of	 retrotransposons	












to	 the	D.	 discoideum	 ENT1	 protein	 in	 adenosine	 transport	 and	 downstream	 effects	 on	 DNA	















Cells	 were	 taken	 from	 storage	 monthly	 and	 grown	 on	 SM	 agar	 plates	 in	 the	 presence	 of	
Raoultella	planticola	before	being	grown	axenically	in	HL5	media	with	1	%	glucose.	HL5	media	
was	 supplemented	 with	 100	 µg/ml	 penicillin	 and	 100	 µg/ml	 streptomycin,	 and	 cells	 were	

























Wild	 type	 (AX3)	D.	 discoideum	 cells	 were	 washed	 in	 phosphate	 buffer	 twice	 (2.2	 g	 KH2PO4	
(monobasic),	0.7	g	K2HPO4	(dibasic)	per	litre)	then	resuspended	in	phosphate	buffer	at	1	x	107	









































Restriction	 digests	 were	 carried	 out	 according	 to	manufacturer’s	 instructions	 (all	 restriction	


























solution	 (50	ml	10%	SDS,	 20	ml	0.5	M	NaOH,	made	up	 to	500	ml)	was	added	and	mixed	by	






















sites	 were	 inserted	 by	 adding	 them	 to	 primers	 used	 to	 create	 the	 knockout	 cassette.	 This	
ensured	that	during	PCR	amplification	of	the	regions	of	ENT1	in	interest,	each	cut	site	was	added.	
The	 arms	 were	 sequentially	 cloned	 into	 the	 pLPBLP	 vector	 at	 sites	 flanking	 the	 blasticidin-



































before	 heat	 inactivation	 for	 5	minutes	 at	 95	 °C.	 2	 µl	 of	 the	 cell	 lysate	was	 analysed	 by	 PCR	
amplification	to	confirm	successful	homologous	integration.		
To	confirm	that	homologous	recombination	resulted	in	ablation	of	ENT1	expression,	RT-PCR	was	



































































analyte	 transitions	 are	 shown	 in	 Supplementary	 Information	 (Table	 S1).	 The	 electrospray	
voltages	 applied	 were	 4.5	 kV	 (positive	 mode)	 and	 -3.5	 kV	 (negative	 mode).	 The	 interface	
temperature,	heat	block	temperature	and	desolvation	line	temperature	were	300	°C,	400	°C	and	
250	 °C	 respectively.	 The	 nebulising	 gas	 and	 drying	 gas	 were	 nitrogen	 at	 3.0	 L/minute	 and	
10	 L/minute	 respectively,	 and	 the	 heating	 gas	 (air)	 was	 delivered	 at	 10	 L/minute.	 Data	was	









200	 ng	DNA	was	 used	 per	 sample	 (measured	 by	Nanodrop)	 and	 total	DNA	methylation	was	
quantified	by	colorimetry-based	immunochemical	binding	of	methylated	DNA	(Antonini	et	al.,	





Universities).	 This	 library	 was	 created	 at	 Cardiff	 University	 by	 transfection	 of	 wild	 type	 D.	
discoideum	(AX4)	with	the	restriction	enzymes	DpnII	and	NlaIII	and	 linearized	DNA	(the	REMI	































quantified	 by	 qPCR	 using	 SYBR®	 Green	 Jump	 StartTM	 Taq	 Ready	Mix,	 as	 per	manufacturer’s	
instructions.	 Fold	 changes	 were	 calculated	 using	 the	 ∆∆-Ct	 method.	 Expression	 levels	 were	




RNA	 was	 extracted	 from	 wild	 type	 D.	 discoideum	 using	 RNeasy	 mini	 kit	 (according	 to	
manufacturer’s	protocol).	DNA	was	removed	from	the	RNA	using	the	DNA-free	kit.	cDNA	was	
synthesised	 using	 the	 RevertAid	 First	 Strand	 cDNA	 Synthesis	 Kit	 using	 oligo(dT)18	 primers	
(according	 to	 the	 manufacturer’s	 protocol).	 The	 D.	 discoideum	 IPMK	 (DDB_G0281737)	 was	
amplified	by	PCR	of	the	dIPMK	gene	cDNA	and	the	human	IPMK	(hIPMK:	Uniprot	Q8NFU5,	NCBI	
GeneID	55847)	was	synthesised	with	D.	discoideum	codon	bias	(GenScript)	and	both	genes	were	
































each	 with	 5%	milk	 Tris-buffer	 saline	 with	 1%	 Tween	 (TBST).	 The	 blots	 were	 incubated	 with	
primary	antibody	(p4EBP1),	at	1	 in	1000	concentration	in	5%	milk	TBST	for	18	hours,	washed	
with	 TBST,	 then	 incubated	 with	 secondary	 antibody	 (anti-rabbit	 (horseradish	 peroxidase	
conjugated))	 at	 1	 in	 5000	 concentration	 in	 5%	milk	 TBST	 for	 1	 hour,	washed	with	 TBST	 and	

























lysates	were	boiled	 in	western	blot	 loading	buffer	at	96°C	 for	6.5	minutes	and	 then	proteins	
were	separated	by	15%	polyacrylamide	gel	run	at	70	volts	for	30	minutes	and	100	volts	for	1	
hour	and	transferred	to	a	0.2μm	PVDF	membrane	for	17	hours.	The	membrane	was	blocked	with	
5%	 milk	 Tris-buffered	 saline	 and	 incubated	 overnight	 at	 4°C	 with	 1:1000	 diluted	 primary	
antibody	p4EBP1,	total	4EBP1,	actin	(loading	control)	in	TBS	with	Tween	20	(TBST)	for	2	hours	at	
room	temperature	with	1:5000	diluted	horseradish	peroxidase-conjugated	secondary	antibody	






Healthy	 volunteers	 (Hv)	 and	 people	 with	 multiple	 sclerosis	 (pwMS)	 attending	 clinics	 at	
Beaumont	Hospital,	Dublin,	Ireland,	were	recruited	for	this	study.	This	experiment	was	carried	
out	by	Lisa	Costelloe,	Dr	Eric	Downer	and	John-Mark	Fitzpatrick.	Written	informed	consent	was	
obtained	 from	each	 participant	 and	 the	 study	 received	 ethical	 approval	 from	 the	Beaumont	
Hospital	 Ethics	 (Medical	 Research)	 and	 the	 Faculty	 of	 Health	 Sciences	 Research	 Ethics	
Committee,	Trinity	College	Dublin,	Ireland.	The	recruitment	of	pwMS	into	the	study	was	via	a	
Consultant	Neurologist	and	all	pwMS	had	a	relapsing-remitting	(RR)	form	of	MS	as	defined	by	
the	 revised	McDonald	 criteria	 (Kurtzke	 1983,	 Polman	 et	 al.,	 2011)	 including	 patient	 history,	
clinical	signs	and	symptoms,	physical	examination	and	adjunctive	diagnostic	tools	including	MRI.	
Some	pwMS	were	on	immunomodulatory	treatment	including	gilenya,	dimethyl	fumarate	and	
plegridy.	 Healthy	 volunteers	 with	 no	 history	 of	 autoimmune,	 cardiovascular,	 respiratory	 or	
degenerative	 disease	 were	 included.	 Healthy	 volunteers	 were	 matched	 based	 on	 age	 and	
gender.	Details	of	participant	demographics	are	presented	in	Table	1.	Primary	peripheral	blood	
mononuclear	 cells	 PBMCs	 were	 prepared	 from	 venous	 whole	 blood	 samples	 by	 way	 of	
venipuncture	(max	50	ml	per	donor	collected	in	EDTA	tubes)	from	healthy	control	participants	
(mean	age	42.0	±	2.6	years;	n	=	6)	and	pwMS	(mean	age	35.3	±	5.0	years;	n	=	6).	PBMCs	were	
isolated	 by	 density	 separation	 over	 Lymphoprep™.	 In	 summary,	 whole	 blood	 samples	 were	
diluted	1:1	with	sterile	PBS	and	gently	overlaid	onto	Lymphoprep.	Each	sample	was	subjected	
to	centrifugation	while	 in	 contact	with	Lymphoprep,	 the	PBMC	 layer	was	 separated,	washed	
with	PBS	and	resuspended	in	RPMI	[supplemented	with	10%	FBS,	penicillin	and	streptomycin	
(100	µg/ml	for	both)].	PBMCs	were	(1x106	cells/ml;	3	ml	per	well)	maintained	in	culture	for	at	
least	 2	 hours	 prior	 to	 treatment	 with	 highly-purified	 CBD	 or	 CBG	 (100	 nM),	 or	 THC:CBD	
combinations	(20	nM:17	nM)	for	24	hours.	
2.2.26	 Western	 blot	 analysis	 of	 mTORC1	 activity	 in	 primary	 peripheral	 blood	
mononuclear	cells	






















If	 data	were	 found	 to	 not	 be	 normally	 distributed	 then	 a	 Kruskal-Wallis	 Test	 with	 a	 Dunn’s	






GraphPad	 Prism	 Software.	 In	 this	 thesis,	 n	 number	 represents	 biological	 replicates	 for	 all	
experiments.		
From	 visual	 inspection	 of	 the	 data,	 homogeneity	 of	 variances	 was	 assumed	 to	 be	 met.	 In	










cannabidiol	 (CBD),	 but	 usually	 lower	 than	 tetrahydrocannabinol	 (THC)	 (Swift	 et	 al.,	 2013).	
However,	both	CBG	and	CBD	are	non-psychoactive,	so	present	a	large	advantage	as	potential	
therapeutics	 with	 fewer	 side	 effects.	 The	 molecular	 mechanisms	 of	 CBG	 are	 relatively	
understudied	compared	to	CBD	and	THC	(Abrams,	2018),	however,	the	three	cannabinoids	share	
a	 similar	 molecular	 structure	 (Figure	 1.1)	 (Hill	 et	 al.,	 2014).	 Given	 that	 C.	 sativa	 extracts	
containing	CBG	are	effective	epilepsy	treatments	(Devinsky,	Verducci,	et	al.,	2018)	and	multiple	
sclerosis	 treatments	 (Serpell	 et	 al.,	 2013),	 it	 remains	 important	 to	 understand	 if	 CBG	 has	
therapeutic	 potential	 (Freeman	 et	 al.,	 2019).	 Therefore,	 this	 chapter	 aimed	 to	 search	 for	
molecular	mechanisms	of	CBG.		
One	molecular	mechanism	of	cannabinoids	that	has	previously	been	examined	is	the	inhibition	
of	 adenosine	 signalling	 and	 transport.	 This	 mechanism	 provides	 a	 therapeutic	 potential	 for	
cannabinoids	 in	 the	 treatment	of	 a	 range	of	diseases	where	adenosine	 signalling	pathway	 is	
impacted	by	disease	pathophysiology.	As	 a	 result,	 adenosine	 signalling	 is	 a	 therapeutic	 drug	
target	for	schizophrenia	(Rosse,	2017),	epilepsy	(Zhang	et	al.,	2018),	Alzheimer’s	disease	(Lee	et	
al.,	2018),	and	acute	kidney	 injury	 (Grenz	et	al.,	2012).	CBD,	a	similar	cannabinoid	 to	CBG,	 is	
known	 to	 inhibit	 adenosine	 transport	 through	 ENT1	 (Carrier	 et	 al.,	 2006;	 Liou	 et	 al.,	 2008).	
Furthermore,	adenosine	transport	is	linked	through	biochemical	pathways	to	DNA	methylation,	
whereby	 intracellular	 adenosine	 levels	 and	 DNA	 methylation	 have	 an	 inverse	 relationship	
(Figure	1.3)	(Hermes	et	al.,	2007;	Williams-Karnesky	et	al.,	2013).	Since	the	study	of	biochemical	
pathways	 in	mammalian	systems	can	be	time-consuming	and	expensive	 (Cosson	et	al.,	2002;	
Steinert	 and	 Heuner,	 2005),	 D.	 discoideum	 can	 be	 employed	 as	 a	 simple	 model	 system	 to	
examine	molecular	mechanisms	 of	 compounds	 (Williams,	 2005;	 R.S.B.	Williams	 et	 al.,	 2006;	




















































































and	 thus	 proteins,	 are	 involved	 compared	 to	 growth,	 potentially	 providing	 different	 cellular	





























ID:	 DDB_G0283439)	was	 found	 in	D.	 discoideum	using	 this	method	 and	 alignment	 of	 the	D.	







protein	 in	D.	 discoideum	was	 therefore	 identified	 as	 an	 adenosine	 signalling-related	 protein	
which	could	be	explored	to	examine	modulation	of	activity	by	CBG.	
In	order	to	examine	potential	effects	of	CBG	on	ENT1	in	D.	discoideum,	a	cell	line	lacking	ENT1	
was	made.	 This	 cell	 line	was	 created	 using	 a	 homologous	 recombination	 plasmid	 containing	
sections	 of	 ENT1	 genomic	 DNA.	 The	 ENT1	 genomic	 DNA	 sections	 were	 synthesised	 by	 PCR	
amplification	of	5’	and	3’	regions	of	the	ENT1	gene,	and	then	each	fragment	was	inserted	into	
opposite	sides	of	a	blasticidin-resistance	gene	in	the	pLPBLP	plasmid	(Figure	3.4	A).	To	ensure	




genomic	 location	 (Figure	 3.5	 A	 and	 B).	 Cells	 found	 to	 have	 undergone	 homologous	
recombination	were	isolated	and	then	reverse	transcriptase	(RT)-PCR	was	carried	out	to	confirm	




fruiting	 bodies	 (scale	 bar:	 1	mm	 for	 top	 view).	B,	 C,	 D:	 In	 the	 presence	 of	 CBG	 (0.5,	 4	 or	 20	 μM),	

























 Ent1 Mus musculus (Q9JIM1)
 Ent1 Rattus norvegicus (O54698)
 Ent1 Homo sapiens (Q99808)
 Ent1 Apis mellifera (A0A087ZYY2)
 Ent1 Drosophila melanogaster (Q9VPP0)
 Ent1 Caenorhabditis elegans (G5EDJ3)
 Ent family protein Dictyostelium discoideum (Q54R17)
 Ent family protein Saccharomyces cerevisiae (P31381)
 Ent1 Arabidopsis thaliana (Q8VXY7)
 Ent1 Solanum tuberosum (F6IA07)
 Ent1 Hordeum vulgare (A0A0H5BZF0)




















(Veltman	 et	 al.,	 2009)).	 To	 ensure	 the	 plasmid	 was	 correctly	 constructed,	 digestion	 with	
restriction	 enzymes	 that	 cleaved	 at	 the	 5’	 and	 3’	 ends	 of	 the	 ENT1	 insert	 was	 carried	 out,	
revealing	that	an	insert	of	the	correct	size	(1293	bp)	for	ENT1	was	present	in	this	plasmid	in	the	
correct	location	(Figure	3.6).	The	whole	gene	was	then	sequenced	on	both	strands	to	ensure	no	
mutations	 were	 introduced	 during	 cloning.	 Thereafter,	 the	 plasmid	 was	 transfected	 into	 D.	
discoideum,	however,	no	RFP	fluorescence	was	visible.	An	ENT1	over-expression	construct	was	
therefore	not	successfully	created.		
	To	 investigate	a	 role	 in	 regulating	 the	 response	of	D.	discoideum	 to	CBG,	ENT1-ablated	cells	
were	examined	for	a	change	in	sensitivity	to	CBG	during	growth.	In	these	experiments,	ENT1-	
Figure	3.4:	Preparing	an	ENT1	knockout	plasmid.	A:	The	ENT1	knockout	plasmid	containing	the	5’	and	
































the	primers	 labelled	on	 the	gene	 (primers	 in	Appendix	9.1).	B	 and	C:	DNA	 from	wild	 type	 (B)	 and	
potential	ENT1	knockout	cells	(C)	was	isolated	and	PCR	amplification	was	used	to	detect	the	presence	
of	the	blasticidin-resistance	gene	inserted	into	the	correct	region	of	ENT1	to	knockout	the	gene.	The	
wild	 type	 cell	 line	 (WT)	 had	 only	 genomic	 control	 (GC)	 bands.	 The	 two	 cell	 lines	 with	 successful	
insertions	of	 the	blasticidin-resistance	gene	 into	 the	 ENT1	 gene	 (KO)	have	 genomic	 control	bands,	
vector	 control	 (VC)	 bands	 and	 knockout	 bands	 (KO).	 The	 unsuccessful	 insertion	 of	 blasticidin-
resistance	 gene	 into	 the	 ENT1	 gene	 (NHI)	 had	 only	 genomic	 control	 and	 vector	 control	 bands.	C:	
Reverse	transcriptase	PCR	of	WT	and	ENT1	KO	strains.	A	PCR	band	of	expected	size	(557	bp)	is	only	
shown	in	cDNA	derived	from	WT	cells	(ENT1	+	RT),	although	cDNA	from	both	WT	and	the	two	mutants	





















































































were	grown	 in	the	presence	of	 increasing	concentrations	of	CBG	in	shaking	 culture	for	one	week.	
Growth	was	calculated	as	a	%	of	each	cell	line	in	control	conditions	(in	the	absence	of	CBG),	n=7.	CBG	
inhibited	growth	in	a	concentration-dependent	manner.	Data	arising	from	comparing	the	growth	rate	




(95%	CI:	0.43	-	0.57	μM).	The	wild	type	(WT)	 IC50	(0.22	μM)	was	significantly	 lower	than	ENT1-	 IC50	
(p<0.01).	 Data	 were	 normally	 distributed	 according	 to	 Shapiro-Wilks.	 A	 one-way	 ANOVA	 with	
Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	test	significance.		






























CBG	 was	 found	 to	 elevate	 extracellular	 adenosine	 in	 microglia,	 the	 effects	 of	 CBG	 on	 a	
downstream	process	of	adenosine	 transport	were	examined.	Adenosine	has	previously	been	
found	 to	 regulate	DNA	methylation	 (Williams-Karnesky	et	 al.,	 2013),	 providing	 a	 readout	 for	
adenosine	 transport-related	 effects	 of	 CBG.	 In	 D.	 discoideum,	 there	 is	 one	 DNA	
methyltransferase	 protein,	 DNMA,	 which	 methylates	 cytosine	 residues	 in	 DNA	 (Uniprot	 ID:	




D.	 discoideum	DNMA	 share	 43.6	%	 identity	 (Clustal	W)	 (Figure	 3.9	 A),	 the	 key	 S-adenosyl-L-






























































ablation	created	a	 reduction	 in	 sensitivity	 to	CBG	 in	D.	discoideum,	 implicating	 the	 signalling	
pathway	 involved	 in	 DNA	 methylation	 and	 adenosine	 transport	 as	 a	 potential	 molecular	
mechanism	for	CBG	in	D.	discoideum.	
In	order	to	 identify	whether	CBG	modulated	DNA	methylation	in	D.	discoideum,	 the	effect	of	
CBG	 treatment	 was	 examined	 in	 this	 model.	 To	 carry	 this	 out,	 wild	 type	 cells	 (AX3)	 were	
maintained	in	control	conditions	(in	the	presence	of	solvent	only)	or	in	the	presence	of	0.25	µM	
CBG	for	24	hours.	Genomic	DNA	was	extracted	and	total	DNA	methylation	was	quantified	by	
colorimetry-based	 immunochemical	 binding	 of	 methylated	 DNA	 (Antonini	 et	 al.,	 2019).	
Treatment	with	CBG	led	to	a	1.6-fold	increase	in	DNA	methylation	in	D.	discoideum	(Figure	3.11	
A)	(P<0.05,	One-Way	ANOVA	with	Dunnett’s	Post-Hoc).	To	determine	if	this	effect	was	related	
to	 adenosine	 signalling,	 wild	 type	 cells	 were	 treated	 with	 an	 ENT	 family	 protein	 inhibitor,	




methylation	 in	D.	discoideum	 (Figure	3.11	A)	 (P<0.01,	One-Way	ANOVA	with	Dunnett’s	Post-
Hoc).	 To	 determine	 if	 these	 effects	 were	 dependent	 on	 ENT1	 transport	 of	 adenosine,	 the	
experiment	was	repeated	in	cells	lacking	the	ENT1	protein.	To	carry	this	out,	ENT1-	cells	were	
maintained	in	control	conditions	(in	the	presence	of	solvent	only)	or	treated	with	0.25	µM	CBG	
or	 5	nM	NBTI	 for	 24	hours.	 Cells	 lacking	 ENT1	had	 an	elevated	basal	 level	 (1.5-fold)	 of	DNA	
methylation	compared	to	wild	type	cells	(P<0.05,	one-way	ANOVA	with	Bonferroni’s	Multiple	
Comparison	Test)	 (Figure	3.11	B).	However,	 treatment	with	CBG	or	NBTI	did	not	significantly	









Dictyostelium discoideum      MEQLRVLEFYSGIGGMHYGLQESGVDFQVIQSFDINTNANLNYKYTFNEDS-SQKSIESY 59
Homo sapiens                  MEPLRVLELYSGVGGMHHALRESCIPAQVVAAIDVNTVANEVYKYNFPHTQLLAKTIEGI 60
** *****:***:****:.*:** :  **: ::*:** **  ***.* . .   *:**. 
Dictyostelium discoideum      SVEELEGFKANAWLMSPPCQPFTRLGLQKDDQDNRTNSFFHLLDVLTKIKDPPTYILIEN 119
Homo sapiens                  TLEEFDRLSFDMILMSPPCQPFTRIGRQGDMTDSRTNSFLHILDILPRLQKLPKYILLEN 120
::**:: :. :  ***********:* * *  *.*****:*:**:* :::. *.***:**
Dictyostelium discoideum      VFGFAKKGSSNTRDHLLDTLIKMNYSFQEFHLSPQQFGLANQRLRYFCIAKRNGKL-NFK 178
Homo sapiens                  VKGFEV---SSTRDLLIQTIENCGFQYQEFLLSPTSLGIPNSRLRYFLIAKLQSEPLPFQ 177
* **     *.*** *::*: : .:.:*** *** .:*: *.***** *** :.:   *:
Dictyostelium discoideum      ----------KEQDKHNEKVDENKLNNNSNNNNEQ-NKYDNL--------KILDHIPGYD 219
Homo sapiens                  APGQVLMEFPKIESVHPQKYAMDVENKIQEKNVEPNISFDGSIQCSGKDAILFKLETAEE 237
* :. * :*   :  *: .::* *   .:*.          ::.   . :
Dictyostelium discoideum      FHTTLE-ECDEISNYFDKDLTDDELYEKYKVPHNLLLSKGMLFDIKQKDSKTSNCVTKSY 278
Homo sapiens                  IHRKNQQDSDLSVKMLKDFLEDDTDVNQYLLPPKSLLRYALLLDIVQPTCRRSVCFTKGY 297
:* . : :.*   : :.. * **   ::* :* : **  .:*:** *  .: * *.**.*
Dictyostelium discoideum      GKFIEGTGSIIQMDNNFKAD-----------INDNKSLIPLKLRYFSPKEITRLHGFPEE 327
Homo sapiens                  GSYIEGTGSVLQTAEDVQVENIYKSLTNLSQEEQITKLLILKLRYFTPKEIANLLGFPPE 357
*.:******::*  ::.:.:            :: ..*: ******:****:.* *** *
Dictyostelium discoideum      FKFSPKLTTIQCYRLIGNSLNVKIVSELLKVLVSPNEEEEQQEQQKEKEGKK* 379
Homo sapiens                  FGFPEKITVKQRYRLLGNSLNVHVVAKLIKILYE------------------- 391






 Dnmt 2 Mus musculus (O55055)
 Dnmt 2 Rattus norvegicus (Q4G073)
 Dnmt 2 Homo sapiens (O14717)
 Dnmt 2 Gallus gallus (Q4W5Z2)
 Dnmt 2 Spodoptera frugiperda (L7MTK8)
 Pmt 1 Schizosaccharomyces pombe (P40999)
 Mt 2 Drosophila melanogaster (Q9VKB3)
 Dnmt 2 Arabidopsis thaliana (F4JWT7)
 Dnma Dictyostelium discoideum (Q54JH6)
 Dnma Cavenderia fasciculata (F4Q2X5)
 Dnmt 1 Homo sapiens (P26358)
 Dnmt 3A Homo sapiens (Q9Y6K1)











































































































































pathways	 were	 examined.	 Using	 this	 approach,	 CBG	 was	 found	 to	 inhibit	 the	 growth	 of	
D.	discoideum	in	a	concentration-dependent	manner,	while	not	affecting	development.	These	
effects	 suggested	 that	 CBG	 had	 specific	 molecular	 mechanisms	 in	D.	 discoideum	 and	 not	 a	
general	 toxic	 effect.	 Then,	 based	 on	 previous	 literature	 identifying	 adenosine	 transport	
regulation	as	a	molecular	mechanism	of	cannabinoids	(Carrier	et	al.,	2006;	Liou	et	al.,	2008),	the	
relationship	between	CBG	and	ENT1	(an	adenosine	transporter)	was	analysed.	A	cell	line	lacking	
ENT1	was	significantly	 resistant	 to	CBG	during	growth.	Further	experiments	 in	microglia	cells	
revealed	 that	CBG	appeared	 to	block	 the	uptake	of	adenosine.	Together	 these	data	 strongly	
implied	 that	 CBG	may	 inhibit	 adenosine	 uptake	 through	 ENT1.	 To	 investigate	 whether	 CBG	
blocked	adenosine	uptake	in	D.	discoideum	the	relationship	between	CBG	and	a	downstream	
signalling	 pathway	 of	 adenosine	 transport,	 DNA	methylation,	was	 analysed.	Here,	 a	 cell	 line	
lacking	DNA	methyltransferase	was	also	found	to	be	resistant	to	CBG	during	growth.	To	confirm	
























































and	 2.1	 µM	 respectively	 (Wilkinson	 and	Williamson,	 2007).	 Previous	 studies	 imply	 a	 similar	
potency	of	CBG	and	other	cannabinoids	 in	mammalian	cells.	However,	data	 in	D.	discoideum	
indicates	that	CBG	inhibits	growth	at	a	slightly	higher	potency	than	other	cannabinoids.		
In	 this	 chapter,	 CBG	 was	 found	 to	 inhibit	 the	 growth	 of	 D.	 discoideum	 cells	 at	 a	 similar	









(Haney	 et	 al.,	 2016).	 Lower	 concentrations	 of	 cannabinoids	 have	 also	 been	 shown	 to	 be	




































extracellular	 level	 of	 adenosine.	 In	 addition,	 DNA	 methylation	 which	 is	 inversely	 related	 to	
adenosine	levels	(Kredich	and	Martin,	1977;	Boison	et	al.,	2002),	is	increased	by	CBG	treatment,	










ENT1	 was	 found	 to	 be	 over-expressed,	 and	 treatment	 with	 ENT1	 inhibitors	 increased	
extracellular	adenosine,	implying	that	in	this	disease	model	intracellular	adenosine	is	lower	than	
extracellular	(Kao	et	al.,	2017).	Previous	studies,	along	with	data	found	in	this	chapter,	indicate	
that	 ENT1	 is	 an	 adenosine	 transporter	 which	 is	 more	 likely	 to	 increase	 adenosine	 uptake.	
Furthermore,	 this	 chapter	 indicates	 that	CBG	may	be	an	 inhibitor	of	ENT1-related	adenosine	





lacking	 the	 adenosine	 transporter	 protein	 ENT1	 are	 resistant	 to	 the	 effects	 of	 CBG	 on	 DNA	
methylation	and	have	a	constitutively	elevated	level	of	DNA	methylation.	The	dysregulation	of	
DNA	methylation	has	been	implicated	in	epileptogenesis,	which	is	the	progression	of	epilepsy,	








adenosylhomocysteine	 which	 is	 converted	 into	 adenosine	 and	 homocysteine.	 The	 reaction	
occurs	 at	 equilibrium	 and	 therefore	 will	 only	 continue	 if	 adenosine	 and	 homocysteine	 are	
continually	 removed.	 Therefore,	 an	 increase	 in	 adenosine	 blocks	 the	 pathway	 and	 results	 in	
decreased	 DNA	methylation	 and	 conversely	 a	 decrease	 in	 adenosine	 allows	 the	 pathway	 to	
continue	and	increases	DNA	methylation	(Kredich	and	Martin,	1977;	Boison	et	al.,	2002).	In	this	
study	we	find	CBG	treatment	and	inhibition	or	removal	of	adenosine	transporters	results	in	an	
increase	 in	DNA	methylation	 in	D.	discoideum.	This	could	be	due	 to	a	decrease	 in	adenosine	
uptake	caused	by	CBG	or	adenosine	transporter	inhibition,	thus	resulting	in	the	continuation	of	
the	 transmethylation	 pathway	 and	 hypermethylation	 of	 DNA.	 As	 CBG	 appears	 to	 modulate	









In	 addition	 to	 adenosine	 signalling	 explored	 in	 the	 previous	 chapter,	 there	 are	 many	 other	
molecular	 mechanisms	 suggested	 for	 cannabinoids.	 These	 proposed	 molecular	 mechanisms	
include	TRPV1	(Borrelli	et	al.,	2014),	GPR55	(Devinsky	et	al.,	2014),	and	the	one-carbon	cycle	and	
methionine	signalling	(Perry	et	al.,	2020).	However,	little	research	has	been	carried	out	into	CBG	










using	 these	 methods	 have	 been	 validated	 in	 mammalian	 models	 (Perry	 et	 al.,	 2020)	 and	























Following	 the	 isolation	 of	 CBG-resistant	mutants,	 each	mutant	was	 analysed	 to	 identify	 the	
molecular	 mechanisms	 controlling	 CBG	 sensitivity.	 In	 each	 mutant,	 a	 restriction	 enzyme-
Figure	 4.1:	 An	 unbiased	D.	 discoideum	 screen	 was	 employed	 to	 find	 CBG-resistant	 mutants.	 A:	
Schematic	of	a	mutant	 library	screen	to	 identify	mutants	resistant	to	the	growth	 inhibition	effect	of	






















mediated	mutational	 insert	 (REMI)	disrupted	expression	of	a	gene,	 leading	to	a	disruption	of	
protein	expression	controlling	CBG	sensitivity.	In	order	to	identify	this	protein,	the	location	of	










line	 contained	 an	 insert	 in	 the	 5’	 region	 of	 the	ORF	 in	 the	DDB_G0292968	 gene	 encoding	 a	
putative	licheninase	protein.	Two	cell	lines	contained	inserts	80	base	pairs	(bp)	downstream	of	
the	ORF	of	the	DDB_G0295181	gene	encoding	a	tRNA-Tyr-GUA-6.	One	cell	contained	an	insert	
in	 the	5’	 region	of	 the	ORF	of	 the	DDB_G0272242	gene,	encoding	 the	 calcium	upregulated	 I	
(CupI)	 protein.	 Three	 cell	 lines	 contained	 inserts	 in	 the	 3’	 region	 of	 the	 ORF	 of	 the	





Figure	4.2:	 Identification	of	 insertion	 sites	 in	CBG-resistant	mutants.	The	 iPCR	of	6	 isogenic	CBG-








determine	 the	 cellular	 roles	 of	 each	 protein.	 In	 order	 to	 carry	 this	 out,	 each	D.	 discoideum	
protein	 was	 analysed	 using	 BLAST	 for	 H.	 sapiens	 orthologues.	 The	 protein	 product	 of	
DDB_G0269494	was	uncharacterised	in	D.	discoideum	with	no	known	function	and	had	no	H.	























N/A DDB_G0269494 1 C-terminus	ORF
Putative licheninase DDB_G0292968 1 N-terminus	ORF
tRNA-Tyr-GUA-6 DDB_G0295181 2 80 bp	downstream	of	ORF
CupI DDB_G0272242 1 N-terminus ORF
RCC1-domain	containing	protein DDB_G0279435 3 C-terminus	ORF






a	 likely	 orthologue	 of	 an	 interesting	 H.	 sapiens	 protein	 domain.	 This	 RC	 protein	 is	 likely	 to	
function	as	a	GTPase	regulator	(Cubillos-Rojas	et	al.,	2014).	In	order	to	determine	the	similarity	








RCC1	domains	 in	 the	HERC2	protein	and	 the	RCC1	domain	 in	 the	D.	discoideum	protein	also	


































contain	 inositol	 phosphate-binding	 domains	 and	 ATP-binding	 domains	 (Figure	 4.5	 B).	
Phylogenetic	analysis	 (using	MEGA	7	to	produce	a	neighbour-joining	tree	with	500	Bootstrap	
replications)	 showed	 the	H.	 sapiens	and	D.	discoideum	 IPMK	proteins	 to	be	within	 the	 same	




et	 al.,	 2012;	 Dailey	 and	 Kim,	 2012;	 Bang	 et	 al.,	 2014).	 The	 IPMK	 protein	 was,	 therefore,	 a	





Figure	 4.4:	 Protein	 sequence	 alignment	 of	 the	H.	 sapiens	HERC2	 protein	 RCC1	 domains	 and	 the	
D.	discoideum	RC	protein.	A:	The	D.	discoideum	RC	protein	the	H.	sapiens	HERC2	protein.	In	black	are	















Comparison	 of	 Homo	 sapiens	 and	 Dictyostelium	 discoideum	 IPMK	 proteins.	 Both	 the	 human	 and	


























plasmid	 was	 transfected	 into	 D.	 discoideum	 and	 presence	 of	 the	 dIPMK-RFP	 protein	 was	
examined	 by	western	 blot	 using	 an	 anti-RFP	 antibody.	 This	 analysis	 found	 that	 dIPMK+	 cells	
showed	 a	 specific	 50	 kDa	 RFP-containing	 protein	 which	 was	 absent	 in	 wild	 type	 cells	 and	
consistent	with	 the	expression	of	 full-length	dIPMK-RFP	 (Figure	4.7	C).	 Furthermore,	 protein	
extracts	from	wild	type	and	dIPMK	over-expressing	cells	(dIPMK+)	cells	contained	a	similar	level	



































































inhibited	 dIPMK+	 cell	 growth	 at	 168	 hours	 (P<0.01,	 Mann	Whitney	 test).	 Data	 arising	 from	
comparing	the	growth	rate	at	differing	concentrations	of	CBG	was	used	to	calculate	a	dIPMK+	
IC50	for	CBG	of	0.64	µM	(Figure	4.8	B),	which	was	significantly	higher	than	the	wild	type	IC50	of	
0.22	 µM	 (P<0.01,	 one-way	 ANOVA	with	 Bonferroni’s	Multiple	 Comparison	 Test	 (Figure	 3.1).	
These	 data	 showed	 dIPMK	 over-expression	 created	 a	 reduction	 in	 sensitivity	 to	 CBG	 in	 D.	






Figure	 4.8:	 Elevated	 IPMK	 leads	 to	 resistance	 to	 CBG	 during	 growth	 in	D.	 discoideum.	A:	 Cells	
over-expressing	dIPMK	(dIPMK+)	were	grown	in	the	presence	of	increasing	concentrations	of	CBG	(and	
solvent	only	control;	0)	for	one	week.	CBG	inhibited	cell	growth	in	a	concentration-dependent	manner	




Wilks.	 A	 one-way	 ANOVA	 with	 Bonferroni’s	 Multiple	 Comparison	 Test	 was	 carried	 out	 to	 test	
significance.		















































































In	 this	 chapter,	 a	 D.	 discoideum	mutant	 library	 was	 employed	 to	 discover	 potential	 novel	
molecular	mechanisms	of	CBG.	In	the	previous	chapter,	CBG	was	found	to	inhibit	the	growth	of	
D.	discoideum	but	not	development.	These	effects	suggested	that	CBG	had	specific	molecular	
mechanisms	 in	D.	discoideum	and	not	a	general	 toxic	effect.	To	 identify	which	proteins	were	
involved	in	this	effect,	a	D.	discoideum	mutant	library	was	screened	for	CBG-resistant	mutants	
and	two	proteins	possibly	 involved	in	the	molecular	mechanisms	of	CBG	were	identified	with	














promoter	 regions	of	genes.	 In	 total,	 insertion	sites	 in	 the	mutant	 library	are	estimated	 to	be	
present	 in	 43	%	of	 the	 genes	 in	 the	D.	 discoideum	 and	 some	genes	 contain	multiple	 unique	
insertion	sites	(Gruenheit	et	al.,	2019).	That	there	is	only	a	43	%	coverage	of	D.	discoideum	genes	
in	 the	 mutant	 library	 limits	 the	 potential	 to	 discover	 proteins	 that	 regulate	 the	 molecular	
mechanism	 of	 CBG	 that	 are	 likely	 to	 be	 lethal	 if	 expression	 is	 ablated	 or	 altered.	 As	 the	










One	protein	potentially	 involved	 in	 regulating	 the	molecular	mechanism	of	CBG	found	 in	 the	






al.,	 2006).	 In	H.	 sapiens,	HERC2	has	ubiquitin	 ligase	activity,	 regulates	 the	activity	of	 tumour	
proteins	p53,	and	is	involved	in	DNA	repair,	cell	cycle,	regulation	and	iron	metabolism	(Cubillos-
Rojas	et	al.,	2016).	Recent	experiments	have	found	that	CBD	has	the	potential	to	treat	Angelman	













































for	 the	 survival	of	D.	discoideum	 (Maag	et	al.,	2011).	The	vital	 role	 for	 IPMK	could	be	 in	 the	
production	 of	 inositol	 pentakisphosphate	 (IP5)	 or	 inositol	 hexaphosphate	 (IP6)	 in	 specific	
morphogenetic	processes	and	cellular	survival	(Frederick	et	al.,	2005).	This	is	likely	to	be	the	case	
as	 IPMK	 from	 Arabidopsis	 thaliana	 expressed	 in	 D.	 melanogaster	 can	 rescue	 the	 lethal	
phenotype	of	IPMK	loss,	and	the	only	activity	of	A.	thaliana	 IPMK	in	D.	melanogaster	was	IP4	
production	(Malabanan	and	Blind,	2016).	Therefore,	efforts	at	creating	a	D.	discoideum	cell	line	
lacking	 IPMK	were	halted	at	 960	attempts.	However,	 future	methods	 could	be	used	 such	as	




To	 determine	 if	 IPMK	 over-expression	 in	 the	 CBG-resistant	 mutant	 was	 responsible	 for	
resistance	to	CBG	during	growth,	a	growth	assay	was	carried	out	with	the	recapitulated	IPMK	
over-expressing	cell	line.	In	this	experiment,	over-expression	of	IPMK	in	D.	discoideum	was	found	
to	 confer	 a	 three-fold	 increase	 in	 resistance	 during	 growth	 to	 CBG	 at	 the	 50	 %	 inhibition	
89	
	

















2005),	histone	de-acetylase	 regulation	 (Watson	et	al.,	 2012),	 and	AMPK	and	LBK1	 regulation	
(Bang	et	al.,	2012;	Dailey	and	Kim,	2012;	Bang	et	al.,	2014).	In	the	mutant	screen,	the	mutagenic	




The	H.	 sapiens	 IPMK	 protein	 has	many	 cellular	 roles	 and	 functions,	making	 it	 an	 interesting	
potential	therapeutic	target.	One	of	the	functions	of	IPMK	is	to	act	as	a	PI3-kinase,	this	regulates	
phosphatidylinositol	 (3,4,5)-trisphosphate	(PIP3)	production	and	may	regulate	transcription	 in	
the	nucleus	 in	yeast	 (Resnick	et	al.,	2005).	The	PI3-kinase	 function	of	 IPMK	activates	protein	
kinase	B	 (PKB)	which	goes	on	 to	activate	mTORC1	activity	 (Maag	et	 al.,	 2011).	 Furthermore,	
through	 non-catalytic	 binding	 with	 mTOR	 and	 Raptor,	 IPMK	 regulates	 mTORC1	 signalling	
independently	of	 this	catalytic	activity	 (Kim	et	al.,	2011).	Therefore,	 through	many	functions,	
IPMK	regulates	mTORC1	activity	(Figure	1.4).	The	function	of	mTORC1	is	to	regulate	cell	growth	
and	 protein	 synthesis	 through	 the	 eukaryotic	 translation	 initiation	 factor	 4E	 (eIF4E)-binding	
protein	(4EBP)	and	cell	size	through	ribosomal	protein	S6	kinase	(S6K)	(Yang	et	al.,	2014).	The	












cellular	 process	 was	 analysed.	 The	 ability	 of	 IPMK	 to	 non-catalytically	 bind	 mTOR	 and	 to	
catalytically	regulate	mTOR	activity	through	PIP3	production	provided	a	mechanism	by	which	to	
measure	the	effect	of	CBG	on	IPMK	activity	(Kim	et	al.,	2011;	Blind	et	al.,	2012).	To	carry	this	out,	
4EBP1	 phosphorylation	 (a	 downstream	 effector	 of	mTORC1	 Figure	 5.1	 A)	 was	measured	 by	
western	blot	analysis,	using	an	antibody	which	binds	to	phosphorylated	threonine	46	in	the	H.	
sapiens	4EBP1	protein.	An	amino	acid	alignment	(using	Clustal	W)	indicated	that	this	threonine	











1.3-fold,	 as	 evidenced	 by	 an	 increase	 in	 the	 phosphorylation	 of	 4EBP1	 compared	 to	 control	
conditions	(P<0.05,	One-Way	ANOVA	with	Dunnett’s	Post-Hoc)	(Figure	5.2).	However,	CBDA	and	
CBDV	did	not	increase	4EBP1	phosphorylation	compared	to	control	conditions.	Together,	these	







hour,	 then	 levels	 of	 phosphorylated	 4EBP1	 were	 measured	 by	 western	 blot.	 In	 control	









Dictyostelium discoideum --------MSTTRAIPVS-------LKDRSDIDFSTSLGGTLYGTTPGGTKIVYDRNALL 45
Homo sapiens            MSGGSSCSQTPSRAIPATRRVVLGDGVQLPPGDYSTTPGGTLFSTTPGGTRIIYDRKFLM 60
: :****.:         :    *:**: ****:.******:*:***: *:
Dictyostelium discoideum QYRNSPLSKTPPPQLAHITNTELNKKVEKSTTTPTTTTPPTTTAK---------PKPTND 96
Homo sapiens            ECRNSPVTKTPPRDLPTIPGVTSP----------SSDEPPMEASQSHLRNSPEDKRAGGE 110
: ****::**** :*  * ..             ::  **  :::          :  .:
Dictyostelium discoideum DDIFPME- 103
Homo sapiens            ESQFEMDI 118























Figure	 5.3:	 Elevation	 of	 IPMK	 abrogates	 the	 effects	 of	 CBG	 and	 CBD	 on	 mTORC1	 activity	 in	 D.	
discoideum.	dIPMK+	cells	were	kept	in	control	conditions	or	treated	with	0.25	μM	CBG	or	CBD	for	1	
hour	and	then	samples	were	analysed	for	phosphorylation	of	4EBP1	by	western	blot,	n=8.	In	control	
conditions,	 dIPMK+	 cells	 had	 elevated	mTORC1	 activity	 compared	 to	 untreated	 wild	 type	 cells,	 as	
evidenced	 by	 an	 elevated	 level	 of	 phosphorylated	 4EBP1.	 In	 dIPMK+	 cells	 both	 cannabinoids	



































Figure	5.2:	CBG	 and	CBD	upregulate	mTORC1	activity	 in	D.	discoideum.	Wild	 type	 (WT)	cells	were	
maintained	in	control	conditions	(in	the	absence	of	CBG,	CBD,	CBDV	or	CBDA	(-))	or	treated	with	0.25	










































(pleckstrin	 homology	 domain,	 protein	 kinase	 domain	 and	 AGC-kinase	 domain)	 with	 the	 H.	
sapiens	protein	 (Figure	5.4	B).	Phylogenetic	analysis	 (using	MEGA	7	 to	produce	a	neighbour-
joining	 tree	with	500	Bootstrap	 replications)	 indicated	 that	PKBA	was	more	 similar	 to	 the	H.	
sapiens	protein	than	PKGB	(Figure	5.4	C).		
Therefore,	 CBG	 growth	 assays	were	 carried	 out	 using	 a	D.	 discoideum	 cell	 line	 lacking	 PKBA	
(PKBA-)	 in	 addition	 to	 a	 cell	 line	 lacking	 PKBA	 and	 over-expressing	 dIPMK	 (PKBA-dIPMK+),	 to	
examine	if	a	reduction	in	PKB	affected	D.	discoideum	sensitivity	to	CBG	during	growth.	In	these	
experiments,	 PKBA-	 and	 PKBA-dIPMK+	 cells	 were	 grown	 in	 the	 presence	 of	 increasing	









IC50	 for	 PKBA-	 cells	 of	 2.16	 µM	 and	 for	 PKBA-dIPMK+	 cells	 of	 1.74	 μM,	 both	 of	 which	 were	
significantly	 higher	 than	 the	 wild	 type	 IC50	 of	 0.22	 µM	 (P<0.01,	 one-way	 ANOVA	 with	
Bonferroni’s	Multiple	Comparison	Test)	(Figure	5.5	C).	In	these	experiments,	over-expression	of	
IPMK	in	PKBA-ablated	cells	did	not	significantly	alter	the	IC50	of	D.	discoideum	treated	with	CBG	














mTORC1	 activity	 compared	 to	 wild	 type	 cells,	 as	 evidenced	 by	 an	 increase	 in	 4EBP1	
phosphorylation	(P<0.01,	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test)	(Figure	
5.6	 B).	 In	 control	 conditions,	 cells	 lacking	 both	 PKBA	 and	 PKGB	 did	 not	 have	 a	 significantly	
different	level	of	mTORC1	activity,	as	evidenced	by	a	similar	level	of	4EBP1	phosphorylation	to	
wild	type	cells	(Figure	5.6	C).	Following	CBG	or	CBD	treatment	of	PKBA-	cells,	mTORC1	activity	
increased	 a	 further	 1.3-	 and	 1.6-fold	 respectively,	 as	 evidenced	 by	 an	 increase	 in	 4EBP1	
phosphorylation	(P<0.05	for	CBG,	P<0.01	for	CBD,	one-way	ANOVA	with	Bonferroni’s	Multiple	
Comparison	Test).	However,	treatment	with	either	CBG	or	CBD	did	not	alter	mTORC1	activity	in	
cells	 lacking	 both	 PKBA	 and	 PKGB,	 as	 evidenced	 by	 no	 change	 in	 the	 level	 of	 4EBP1	
phosphorylation	(one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test).	In	combination,	








share	a	sequence	 identity	of	44.5	%.	Asterisks	 identical,	 colons	highly	similar,	 full	stops	 similar.	B:	
Comparison	 of	 H.	 sapiens	 PKB	 and	 D.	 discoideum	 PKBA	 proteins.	 Both	 proteins	 share	 pleckstrin	





Dictyostelium discoideum      MSTAPIKHEGFLTKEGGGFKSWKKRWFILKGGDL-SYYKTKGELV-----PLGVIHLNTS 54
Homo sapiens                  MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQC 60
** . * :**:* *.*  :*:*: *:*:**...    ** : : *     **. : :  .
Dictyostelium discoideum      GHIKNSDRKKRVNGFEVQTPSR----TYFLCSETEEERAKWIEILINERE---------L 101
Homo sapiens                  QLMKT--ERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEM 118
:*.  .: * * * ::  .        :  ** *** :*   : .  :         :
Dictyostelium discoideum      LLNGGK-------------QPKKSEKVGVADFELLNLVGKGSFGKVIQVRKKDTGEVYAM 148
Homo sapiens     DFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAM 178
:..*.               * ..:* : :** *:*:***:***** *::* **. ***
Dictyostelium discoideum      KVLSKKHIVEHNEVEHTLSERNILQKINHPFLVNLNYSFQTEDKLYFILDYVNGGELFYH 208
Homo sapiens                  KILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFH 238
*:*.*: ** ::** ***:*..:**: .****. *:*****.*:* *:::*.******:*
Dictyostelium discoideum      LQKDKKFTEDRVRYYGAEIVLALEHLHL-SGVIYRDLKPENLLLTNEGHICMTDFGLCKE 267
Homo sapiens                  LSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKE 298
*.::: *:***.*:****** **::**  ..*:***** ***:* ::*** :********
Dictyostelium discoideum      GLLTPTDKTGTFCGTPEYLAPEVLQGNGYGKQVDWWSFGSLLYEMLTGLPPFYNQDVQEM 327
Homo sapiens                  GIKDG-ATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKL 357
*:     .  **************:.*.**: ****.:* ::***: *  ****** :::
Dictyostelium discoideum      YRKIMMEKLSFPHFISPDARSLLEQLLERDPEKRLAD----PNLIKRHPFFRSIDWEQLF 383
Homo sapiens                  FELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVY 417
:. *:**:: **: :.*:*:***. **::**::**..     : * :* ** .* *::::
Dictyostelium discoideum      QKNIPPPFIPNVKGSADTSQIDPVFTDEAPSLTMA-----GECALNPQQQKDFEGFTYVA 438
Homo sapiens                  EKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMEC-VDSERRPHFPQFSYSA 476
:*:: *** *:*...:**  :*  ** :  ::*        ** :: ::: .*  *:* *
Dictyostelium discoideum      ESEHLR* 444



















measured	 by	 western	 blot.	 This	 analysis	 found	 no	 change	 in	 mTORC1	 activity	 in	 cells	 with	
pharmacologically	 inhibited	PI3K	activity	when	 treated	with	CBG	or	CBD,	as	evidenced	by	no	









found	 between	 PKBA-	 and	 PKBA-dIPMK+	 cells.	 Data	 were	 normally	 distributed	 with	 Shapiro-Wilks	
therefore	one-way	ANOVA	with	Bonferroni’s	Multiple	Comparison	Test	was	carried	out	to	determine	
significance.		


















































































































used	as	a	 control	protein	 to	 show	 that	protein	 levels	were	 consistent	between	 samples.	Data	 shown	
represents	mean±standard	error	of	the	mean.	Normality	of	data	was	determined	by	the	Shapiro-Wilk	test	































































































































with	 Dunn’s	Multiple	 Comparison	 Post-test).	 Repeating	 this	 analysis	 in	 cells	 over-expressing	
dIPMK	found	that	 the	CBG-	and	CBD-dependent	elevated	of	 IP6	 levels	are	 lost	 (Figure	5.7	C).	



































































and	 the	 roles	of	 IPMK,	PKB	and	PI3K	 in	 these	effects	were	examined.	As	 IPMK	 is	 involved	 in	
mTORC1	 signalling,	 the	 effects	 of	 CBG	 and	 other	 cannabinoids	 on	 mTORC1	 activity	 were	
measured	through	phosphorylation	of	4EBP1.	Using	this	approach,	CBG	and	CBD	were	found	to	
elevate	mTORC1	activity	in	wild	type	D.	discoideum	cells,	an	effect	not	shared	by	CBDA	or	CBDV.	
Following	 this,	 dIPMK-overexpression	 was	 found	 to	 result	 in	 an	 elevated	 level	 of	 mTORC1	
activity,	 however,	 CBG	 and	 CBD	 reduced	mTORC1	 activity	 in	 dIPMK	over-expressing	 cells.	 In	
addition,	 PKBA	 ablation	 resulted	 in	 an	 increased	 mTORC1	 activation,	 while	 CBG	 and	 CBD	











Cardenal-Muñoz	et	 al.,	 2017;	Chang	et	 al.,	 2020).	However,	 in	D.	discoideum	an	antibody	 to	
detect	total	levels	of	the	4EBP1	protein	is	not	available	(Chang	et	al.,	2020).	Therefore,	it	is	not	
possible	 to	 determine	 whether	 a	 proportion	 of	 phosphorylated	 4EBP1	 is	 changed	 or	 if	 the	
proportion	 of	 phosphorylated	 protein	 remains	 the	 same	 but	 the	 total	 amount	 of	 protein	





other	 cannabinoids	 were	 also	 examined	 to	 determine	 any	 shared	 molecular	 targets	 in	 D.	
101	
	
discoideum.	 Interestingly,	 CBG	 and	 CBD	 both	 increased	 mTORC1	 activity	 in	 wild	 type	 D.	
discoideum	cells,	however,	two	closely	related	cannabinoids,	CBDV	and	CBDA	did	not	have	this	












In	 addition	 to	 CBG	 activation	 of	 mTORC1	 activity,	 dIPMK	 over-expression	 in	 D.	 discoideum	
increased	mTORC1	activity,	mimicking	the	treatment	of	wild	type	cells	with	CBG	or	CBD.	In	this	







leaving	 cells	 with	 a	 reduced	 PI3K/PKB	 signalling	 pathway	 necessary	 for	 the	 activation	 of	
mTORC1.	 In	 this	 case,	 CBG	 or	 CBD	 treatment	 would	 increase	 IPMK	 direct	 involvement	 in	
mTORC1	function,	and	a	reduction	in	PIP3	production	in	the	cell,	therefore	reducing	mTORC1	





these	 data	 suggest	 a	 novel	 mechanistic	 insight	 into	 CBG-	 and	 CBD-dependent	 regulation	 of	

















activity	 of	 the	 other	 protein.	 If	 CBG	 acts	 on	 an	 activity	 specific	 to	 PKBA,	while	 PKGB	 acts	 to	




To	 further	 determine	 the	 effect	 of	 CBG	 on	 IPMK	 and	 PKB	 activities,	 higher	 order	 inositol	
phosphate	levels	were	measured.	IPMK	catalyses	the	production	of	IP4	and	IP5	and	is	therefore	
necessary	for	both	IP6	and	IP7	production	(Chakraborty	et	al.,	2010).	Both	CBG	and	CBD	were	




















CBG.	 The	 observed	 change	 in	 IP6	 levels	 in	 this	 chapter	 suggests	 that	 CBG	 and	CBD	 alter	 the	
production	of	 inositol	phosphates	and	 therefore	may	affect	 IP7	 levels.	 Therefore,	 a	potential	
mechanism	of	action	of	CBG	through	regulation	of	mTORC1	through	IPMK	in	D.	discoideum	 is	





























cytokines	which	 increase	 the	progression	of	MS	 (Simpson	et	 al.,	 2015).	 These	 cells	 include	T	
lymphocytes,	B	cells	and	monocytes	(Yu	et	al.,	2007)	that	become	activated	in	individuals	with	
MS,	crossing	the	blood-brain	barrier	and	leading	to	axonal	degradation	and	myelin	damage	in	
the	 central	 nervous	 system	 (CNS)	 (Bar-Or	 et	 al.,	 2003).	 In	 these	 cells,	 there	 is	 often	 an	
overactivation	of	mTORC1	activity	and	overproduction	of	pro-inflammatory	cytokines	(Carbone	












the	 RFP-containing	 plasmid	 (Figure	 6.1	 A)	 (pDM324	 (Veltman	 et	 al.,	 2009)).	 To	 ensure	 the	
plasmid	was	constructed	correctly,	digestion	with	restriction	enzymes	that	cleaved	at	the	5’	and	
3’	ends	of	 the	hIPMK	 insert	confirmed	that	an	 insert	of	 the	correct	size	 (1260	bp)	 for	hIPMK	
existed	in	this	plasmid	in	the	correct	location	(Figure	6.1	B).	The	whole	gene	was	sequenced	to	
ensure	no	mutations	had	occurred.	Thereafter,	the	plasmid	was	transfected	into	D.	discoideum	
and	 presence	 of	 the	 hIPMK-RFP	 protein	 was	 examined	 by	 western	 blot	 using	 an	 anti-RFP	
antibody.	This	analysis	revealed	that	hIPMK-expressing	cells	(hIPMK+)	showed	a	specific	75	kDa	
RFP-containing	protein,	absent	in	wild	type	cells	and	consistent	with	the	expression	of	full-length	






analysis	 indicated	 that	 RFP-only	 localised	 mainly	 to	 the	 cytoplasm	 (Figure	 6.1	 D),	 while	
hIPMK-RFP	was	primarily	localised	in	the	nucleus,	with	some	cytoplasmic	localisation	(Figure	6.1	
E)	 as	 occurs	 in	 human	 cells	 (Nalaskowski	 et	 al.,	 2002).	 This	 contrasts	 with	 the	 previously	









cell	 growth	 showed	 a	 lag	 phase	 until	 96	 hours,	 an	 exponential	 phase	 to	 144	 hours	 and	 a	
stationary	phase	starting	at	168	hours	(Figure	6.2	A).	Similarly	to	wild	type	cells	(Figure	3.1),	CBG	

















































a	 2.2-fold	 increase	 in	 mTORC1	 activity,	 as	 evidenced	 by	 an	 elevated	 level	 of	 4EBP1	



















































































To	 examine	 if	 the	 CBG-	 and	 CBD-dependent	 regulation	 of	mTORC1	 activity	 was	 shared	 in	 a	
mammalian	model,	mouse	embryonic	fibroblasts	(MEFs)	were	examined.	Here,	wild	type	MEF	
cells	were	maintained	 in	 control	 conditions	 (in	 the	presence	of	 solvent	only)	or	 treated	with	
4	 µM	 CBG	 or	 CBD	 for	 24	 hours,	 then	 the	 levels	 of	 phosphorylated	 and	 total	 4EBP1	 were	
quantified	by	western	blot.	In	these	cells,	mTORC1	activity	was	significantly	elevated	1.5-fold	by	
CBG	or	CBD	treatment,	as	evidenced	by	an	increase	in	the	proportion	of	phosphorylated	4EBP1	












































one-way	 ANOVA	with	Dunnett's	Multiple	 Comparison	 Test)	 and	 an	 unchanged	 level	 of	 total	
4EBP1	 (Figure	 6.4	 C)	 (one-way	 ANOVA	 with	 Dunnett's	 Multiple	 Comparison	 Test).	 In	
combination,	 these	 data	 showed	 CBG-	 and	 CBD-dependent	 elevation	 of	 mTORC1	 activity	
occurred	in	wild	type	MEFs.	
To	assess	whether	 IPMK	signalling	was	necessary	 for	CBG-	and	CBD-dependent	 regulation	of	
mTORC1	activity,	MEF	cells	lacking	the	IPMK	protein	were	examined	for	response	to	CBG	and	
CBD.	Here,	MEF	cells	 lacking	 the	 IPMK	protein	 (Kim	et	al.,	 2011)	were	maintained	 in	 control	
conditions	(in	the	presence	of	solvent	only)	or	treated	with	4	µM	CBG	or	CBD	for	24	hours,	then	
the	levels	of	phosphorylated	and	total	4EBP1	were	quantified	by	western	blot.	In	these	cells,	no	
significant	 change	 was	 observed	 in	 mTORC1	 activity	 after	 treatment	 with	 CBG	 or	 CBD,	 as	
evidenced	by	no	change	in	the	proportion	of	phosphorylated	4EBP1	to	total	4EBP1	(Figure	6.5	
A)	(one-way	ANOVA	with	Dunnett's	Multiple	Comparison	Test).	Treatment	with	CBG	or	CBD	did	
not	 significantly	 alter	 the	 phosphorylation	 of	 4EBP1	 (Figure	 6.5	 B)	 (one-way	 ANOVA	 with	
Dunnett's	Multiple	Comparison	Test)	or	total	4EBP1	levels	(Figure	6.5	C)	(one-way	ANOVA	with	




















































































Data	 shown	 represents	mean±	 standard	 error	 of	 the	mean.	 Data	 were	 normally	 distributed	 with	












western	 blot.	 These	 experiments	 showed	 that	 no	 significant	 change	 in	mTORC1	 activity	was	
observed	in	MEF	cells	lacking	PI3K	activity	when	treated	with	CBG	or	CBD,	as	evidenced	by	no	






















































































fibroblasts.	A-C:	MEF	 cells	 lacking	 the	 IPMK	protein	were	maintained	 in	 control	 conditions	 (in	 the	



























treatment	 (P=0.59),	 however,	 a	 nonsignificant	 trend	 towards	 a	 decrease	 in	 total	 4EBP1	was	
observed	following	CBG	treatment	(P=0.13)	and	following	THC:CBD	treatment	(P=0.13)	(Mann-
Whitney	 Test).	 In	 combination,	 these	 data	 showed	 a	 CBG-,	 CBD-	 and	 THC:CBD-dependent	








as	 evidenced	 by	 the	 proportion	 of	 phosphorylated	 4EBP1	 compared	 to	 total	 4EBP1	 (P<0.05,	
Mann-Whitney	 Test)	 (Figure	 6.8	 A).	 Furthermore,	 cells	 derived	 from	 patients	 with	 multiple	
sclerosis	 showed	 a	 significant	 3.5-fold	 higher	 level	 of	 phosphorylated	 4EBP1	 than	 cells	 from	
healthy	 volunteers	 (P<0.01,	Mann-Whitney	 Test)	 (Figure	 6.8	 B).	 In	 addition,	 a	 nonsignificant	
trend	 towards	 an	 elevated	 level	 of	 total	 4EBP1	 was	 observed	 between	 cells	 from	 healthy	







cells	 from	 healthy	 volunteers,	 cells	 from	 patients	 with	MS	 were	 tested	 for	 CBG-,	 CBD-	 and	
THC:CBD-dependent	regulation	of	mTORC1	activity.	Here,	primary	PBMCs	were	extracted	from	
patients	with	multiple	sclerosis	and	maintained	in	control	conditions	(in	the	presence	of	solvent	


































































































following	 THC:CBD	 treatment	 (P=0.24)	 treatment	 was	 observed.	 In	 combination,	 these	 data	





protein	was	not	visualised	 (Figure	6.10),	and	no	additional	 sample	 from	this	experiment	was	





















Age Sex Treatment Disease	
duration	
(months)
37 Male Previously	on	Gilenya- stopped	recently 120
21 Female None 48
55 Male Tecfidera 20+years
41 Female Plegridy 13
25 Female None 6










































































































































































































































Figure	 6.8:	 PBMCs	 from	 healthy	 volunteers	 and	 patients	 with	 multiple	 sclerosis	 have	 different	


























































































































































































































































































PBMCs	 from	 patients	 with	 MS.	 A-I:	 Primary	 PBMCs	 from	 patients	 with	multiple	 sclerosis	 were	
maintained	in	control	conditions	(in	the	absence	of	CBG,	CBD	or	THC	(-))	or	treated	with	0.1	μM	CBG	
or	CBD	or	0.02:0.017	µM	THC:CBD	for	24	hours	and	analysed	for	phosphorylated	and	total	4EBP1	
levels.	Actin	was	used	as	a	 control	protein	 to	 show	 that	protein	 levels	were	 consistent	between	

















with	multiple	sclerosis	(PwMS).	A:	Protein	 ladder	(Pageruler	Plus	Prestained	 ladder),	 indicating	the	
size	of	proteins	in	the	western	blot.	B:	Western	blot	showing	the	presence	of	phosphorylation	4EBP1	
and	actin	in	PBMCs.	C:	Western	blot	showing	the	presence	of	total	4EBP1	in	PBMCs.	D:	Western	blot	

























CBD	resulted	 in	a	decrease	 in	mTORC1	activity,	 in	contrast	to	an	 increase	 in	mTORC1	activity	
following	CBG	or	CBD	treatment	of	wild	type	cells	(Figure	5.2).	The	effect	of	CBG	and	CBD	on	
mTORC1	 activity	was	 then	 examined	 in	wild	 type	mouse	 embryonic	 fibroblasts.	 In	wild	 type	




human	cells.	 In	 cells	 from	healthy	volunteers	CBG,	CBD	and	a	mixture	of	THC	and	CBD	were	




in	 regulating	 response	 to	 CBG	 and	 CBD.	 In	 the	 previous	 chapter	 over-expression	 of	 the	


















in	 hIPMK+	 cells.	 Alternatively,	 the	 difference	 could	 be	 a	 result	 of	 the	 increased	 nuclear-
localisation	 of	 the	 human	 protein	 (Nalaskowski	 et	 al.,	 2002),	 as	 observed	 by	 fluorescence	
microscopy.	 In	 the	 nucleus,	 IPMK	may	 act	 through	 PI3K	 activities	 to	mediate	 transcriptional	
control	 or	 export	 of	 nuclear	mRNA	 (Blind	 et	 al.,	 2012).	 Furthermore,	 IPMK	may	 act	 to	 alter	
chromatin	 structure	 and	 global	 transcription	 through	 inositol	 phosphate	 production,	 which	
increases	histone	deacetylation	(Watson	et	al.,	2012;	Millard	et	al.,	2013).	Finally,	IPMK	directly	
binds	 transcription	 factors,	 such	 as	 serum	 response	 factor	 (SRF)	 (Kim	 et	 al.,	 2013),	 cAMP-
response	element-binding	protein	(CREB)	binding	protein	(CBP)	(Xu	et	al.,	2013(a)),	and	p53	(Xu	
et	al.,	2013(b))	and	could,	therefore,	lead	to	the	transcriptional	control	of	a	specific	set	of	genes.	
The	 role	of	 IPMK	 in	 transcriptional	 regulation	was	beyond	 the	 scope	of	 this	 study,	however,	
future	experiments	could	examine	the	links	between	cannabinoid	treatment	and	transcriptional	
differences	 in	 IPMK-regulated	 gene	 expression.	 Regardless,	 this	 chapter	 shows	 a	 conserved	
















humans	 when	 cannabinoids	 are	 orally	 administered,	 and	 therefore	 was	 chosen	 for	 these	
experiments.	Interestingly,	a	much	lower	concentration	of	0.02	µM:0.017	µM	of	a	combination	













CBD	treatment.	This	 indicated	that	 IPMK	activity	was	necessary	 for	 the	elevation	of	mTORC1	
activity	found	in	wild	type	cells.	In	addition,	treatment	with	a	pharmacological	PI3K	inhibitor	also	
resulted	in	a	block	of	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity,	suggesting	that	
PI3K	 signalling	 is	 necessary	 for	 these	 effects.	 Previous	 research	 has	 indicated	 that	 the	 PI3K	
activity	of	IPMK	may	be	responsible	for	50	%	of	the	production	of	PIP3	in	MEF	cells	(Maag	et	al.,	
2011).	Therefore,	the	block	in	CBG-	and	CBD-dependent	elevation	of	mTORC1	activity	 in	cells	
lacking	 IPMK	 or	 PI3K	 activity	 could	 be	 directly	 related.	 This	 would	 imply	 that	 CBG	 and	 CBD	
regulate	the	PI3K	activity	of	IPMK	and	that	this	is	responsible	for	the	increase	in	mTORC1	activity	
observed	 in	 wild	 type	MEFs.	 Alternatively,	 CBG	 and	 CBD	may	 alter	 another	 aspect	 of	 IPMK	
activity,	such	as	mTORC1	binding	(Kim	et	al.,	2011)	or	IP6	production	(Kim	et	al.,	2017),	and	this	
activity	 in	 addition	 to	 a	 functional	 PI3K	 signalling	 pathway	 is	 necessary	 for	 CBG-	 and	 CBD-






Findings	 in	 this	 study	 indicate	 that	 PBMCs	 from	MS	 patients	 contain	 constitutively	 elevated	
mTORC1	activity	compared	to	cells	from	healthy	volunteers	and	that	treatment	with	CBG,	CBD	
or	THC:CBD	reduced	mTORC1	activity	in	cells	from	patients	with	MS.	Previous	research	found	
that	 activation	 of	 immune	 cells,	 such	 as	 those	 present	 in	 PBMCs,	 occurs	 through	 elevated	
mTORC1	signalling	(Gao	et	al.,	2015;	Herrero-Sánchez	et	al.,	2016).	The	activation	of	cells	present	
in	 PBMCs	 leads	 to	 the	 autoimmune	 inflammation	 that	 causes	 demyelination	 of	 neurons	
(Hasheminia	et	al.,	2014).	Previous	studies	found	that	CBD	can	decrease	the	activation	of	these	








In	 immune	 cells	 constituent	 in	 PBMCs,	 mTOR	 activation	 results	 in	 NF-κB	 (nuclear	 factor)	
activation	and	nuclear	translocation	(Gao	et	al.,	2015).	NF-κB	is	a	pro-inflammatory	transcription	
factor,	binding	specific	DNA	sequences	and	promoting	the	transcription	of	inflammatory	actors,	
such	 as	 TNF-α	 (tumour	 necrosis	 factor)	 and	 IL-6	 (interleukin)	 (Wu	 et	 al.,	 2011;	 Hayden	 and	
Ghosh,	2012).	Blocking	mTOR	activity	in	bone	marrow,	the	progenitor	tissue	of	immune	cells,	
results	in	an	inhibition	of	cell	proliferation	(Costa	et	al.,	2006).	mTOR	inhibition	has	also	been	
found	 to	 supress	NF-κB	and	as	a	 result	 reduce	 IL-6	expression	 (Müller-Krebs	et	 al.,	 2013).	 In	
immune	cells,	the	mTOR	pathway	controls	proliferation,	cell	cycle	progression,	differentiation,	
survival,	migration	 and	metabolism	 (Herrero-Sánchez	 et	 al.,	 2016).	 In	 fact,	 PI3K	 inhibitors	 or	
mTOR	inhibition	are	capable	of	blocking	T	cell	proliferation	and	activation	(Herrero-Sánchez	et	
al.,	2016).	mTOR	inhibition	in	T	cells	also	reduces	the	total	4EBP1	(Herrero-Sánchez	et	al.,	2016),	






or	 aggravative	 factor	 and	 therefore	modulation	 of	mTOR	 is	 seen	 as	 a	 potential	 therapeutic	
pathway.	 In	 some	 studies,	 cannabinoids	 have	 been	 found	 to	 reduce	 mTOR	 activity,	 as	 is	
consistent	with	the	finding	in	this	chapter	that	CBG,	CBD	and	THC:CBD	reduce	mTOR	activity	in	
PBMCs	 from	patients	with	MS.	 In	 a	 zebrafish	model	 of	 tuberosclerosis	 complex	 disease,	 the	
disease	model	was	found	to	have	constitutively	elevated	mTOR	signalling	and	CBD	reduced	this	
mTOR	pathway	activation	(as	assessed	by	abundance	of	phosphorylated	S6	kinase)	(Serra	et	al.,	
2019).	 In	addition,	 in	breast	cancer	cell	 lines	 in	which	constitutively	elevated	mTOR	signalling	
occurs,	 CBD	 reduced	 mTOR	 pathway	 activation	 (assessed	 by	 analysis	 of	 the	 proportion	 of	
phosphorylated	4EBP1)	(Shrivastava	et	al.,	2011;	Sultan	et	al.,	2018).	In	other	disease	models,	
mTORC1	 activity	 is	 activated	 during	 treatment	with	 cannabinoids,	 consistent	with	 the	 CBG-,	
CBD-dependent	activation	of	mTORC1	activity	observed	in	wild	type	mouse	cells	and	primary	
PBMCs	 from	 healthy	 volunteers	 found	 in	 this	 thesis.	 In	 neurons	 of	 a	 mouse	 experimental	
autoimmune	 encephalomyelitis	 model	 of	MS,	 mTOR	 activity	 was	 found	 to	 be	 constitutively	
reduced,	 and	 CBD	 elevated	 mTOR	 activity	 to	 normal	 levels	 (assessed	 by	 analysis	 of	 the	
122	
	
proportion	 of	 phosphorylated	 S6	 kinase,	 mTOR	 and	 PKB)	 (Giacoppo	 et	 al.,	 2017).	 CBD	 also	
treated	 symptoms	 of	 an	 amphetamine-induced	 rat	 model	 of	 schizophrenia,	 and	 elevated	
mTORC1	activity	(assessed	by	analysis	of	the	proportion	of	phosphorylated	S6	kinase	and	mTOR)	
(Renard	et	al.,	 2016).	The	mechanisms	behind	 these	apparently	 contradictory	effects	of	CBD	
treatment	are	unknown,	however,	this	thesis	finds	the	two	opposite	effects	of	CBD-dependent	
mTOR	regulation	occur	in	both	D.	discoideum	and	primary	PBMCs	from	humans.	In	this	study,	
the	 opposite	 effects	 of	 cannabinoid	 treatment	 on	mTORC1	 activity	 appear	 to	 be	 dependent	














enhancing	 toll-like	 receptor	 (TLR)	 signalling	 in	 macrophages,	 by	 stabilising	 tumour	 necrosis	
factor	 (TNF)	 receptor-associated	 factor	 6	 (TRAF6)	 (Kim	 et	 al.,	 2017).	 IPMK	 depletion	 in	
macrophages	reduces	TNF-signalling	and	reduces	pro-inflammatory	cytokine	production,	which	

































while	 leaving	 intracellular	 adenosine	 unchanged,	 implying	 that	 CBG	 may	 block	 adenosine	
transport	 into	microglia	 cells.	 As	 adenosine	 transport	 regulates	 DNA	methylation	 (Williams-




pharmacological	 inhibition	 of	 ENT1,	 and	 ablation	 of	 ENT1	 were	 all	 found	 to	 elevate	 DNA	
methylation	 in	 D.	 discoideum,	 while	 ENT1	 ablation	 blocked	 the	 effects	 of	 CBG	 on	 DNA	
methylation.	These	results	indicate	that	CBG	functions	in	a	similar	mechanism	to	CBD	through	




The	 second	 approach	 to	 identify	 molecular	 mechanisms	 for	 CBG	 in	 D.	 discoideum	 was	 an	
unbiased	approach.	Here,	a	mutant	library	was	screened	to	identify	proteins	responsible	for	CBG	
sensitivity	 during	 growth	 in	 D.	 discoideum.	 This	 method	 identified	 two	 potential	 proteins	
involved	in	the	molecular	mechanisms	of	CBG	which	had	H.	sapiens	orthologues,	thus	allowing	
for	translational	experiments.	The	two	proteins	identified	were	the	regulator	of	chromosome	
















of	 IPMK	activity	 in	D.	discoideum	 in	a	PKB-	and	PI3K-dependent	manner	to	regulate	mTORC1	
activity.	
To	 confirm	 the	 therapeutic	 relevance	 of	 the	 IPMK	 dependent	 mechanism	 proposed	 in	 D.	




lacking	 IPMK,	 or	 with	 pharmacologically	 inhibited	 PI3K	 activity,	 CBG	 and	 CBD	 did	 not	 affect	
mTORC1	 activity.	 This	 indicated	 that	 both	 CBG	 and	 CBD	 elevate	 mTORC1	 activity	 in	 D.	
discoideum	and	mammalian	cells	and	that	this	is	dependent	upon	IPMK	and	PI3K	in	mammalian	
cells.	 To	 investigate	 the	 therapeutic	 relevance	 of	 these	 findings,	 primary	 peripheral	 blood	
mononuclear	cells	(PBMCs)	from	healthy	volunteers	and	patients	with	MS	were	examined,	since	























found	 that	 THCA	 and	 CBGA	 had	 synergistic	 cytotoxic	 effects	 against	 colon	 cancer	 cells	





cannabinoids	 need	 to	 be	 carried	 out	 to	 establish	 the	 optimal	 combination	 for	 each	 specific	
potential	therapeutic	mechanism.		
7.4	Links	to	previously	suggested	molecular	mechanisms	of	cannabinoids	
Previous	 studies	 have	 indicated	 that	 the	molecular	mechanisms	 of	 phytocannabinoids	 could	
include	 cannabinoid	 receptors	 (Arévalo-Martín	 et	 al.,	 2003),	 adenosine	 (Carrier	 et	 al.,	 2006),	
TRPV1	(Borrelli	et	al.,	2014),	GPR55	(Devinsky	et	al.,	2014),	glycine	and	the	one-carbon	cycle	
(Perry	et	al.,	2020),	as	well	as	PI3K/PKB/mTOR	activity	(Giacoppo	et	al.,	2017).	This	thesis	adds	




modulator	 of	 CBG	 and	 CBD	 activity	 on	 mTORC1	 signalling.	 Furthermore,	 the	 mechanisms	
proposed	 in	 this	 thesis	 may	 relate	 to	 or	 overlap	 with	 several	 of	 the	 existing	 mechanisms	
suggested	for	cannabinoids.	The	potential	CBD	molecular	mechanism	of	glycine	and	one-carbon	
cycle	 regulation	 may	 be	 related	 to	 adenosine	 transport	 and	 DNA	 methylation,	 as	 both	 are	
involved	in	the	same	pathway	(Perry	et	al.,	2020).	Furthermore,	TRPV1	has	been	implicated	as	
an	upstream	regulator	of	mTORC1,	potentially	through	AMPK	(Maiese,	2017;	Bort	et	al.,	2019),	
however	 since	 this	 cannabinoid	 receptor	 is	 not	 found	 in	 D.	 discoideum	 (McPartland	 et	 al.,	









model	 through	 adenosine	 transport	 inhibition.	 In	 addition,	 CBD	 enhanced	 the	 adenosine-
dependent	suppression	of	TNF-α	in	the	diabetes	model	(Liou	et	al.,	2008).	The	suppression	of	







This	 anticonvulsant	 effect	 occurs	 through	 upregulation	 of	 presynaptic	 inhibition	 of	 neurons,	
which	prevents	runaway	excitation	in	feed-forward	synaptic	circuits	(Huber	et	al.,	2001;	Boison,	
2012)	and	stabilises	the	postsynaptic	membrane	potential	(Figure	7.1	A)	(Baldwin	et	al.,	2004).	












also	 inhibit	 adenosine	 uptake	 through	 ENT1,	 mimicking	 the	 ENT	 inhibitor	 NBTI,	 implies	 a	
potential	shared	mechanism	with	CBD	and	future	therapeutic	possibilities	for	the	treatment	of	
epilepsy.	 To	 examine	 this,	D.	 discoideum	 intra-	 and	 extracellular	 adenosine	 levels	 could	 be	
measured	during	treatment	with	CBG	and	compared	to	CBD	treatment.		
Our	research	indicates	that	in	D.	discoideum	CBG	modulates	DNA	methylation,	a	downstream	





and	 CBG	both	 increased	DNA	methylation	 at	 the	 keratin	 10	 gene,	while	 only	 CBD	 increased	
global	 DNA	 methylation	 levels	 (Pucci	 et	 al.,	 2013).	 The	 CBG-dependent	 increase	 in	 DNA	
methylation	 in	 D.	 discoideum	 implies	 that	 CBG	 blocks	 the	 uptake	 of	 adenosine	 into	 D.	
discoideum,	leading	to	a	greater	extracellular	concentration	of	adenosine	and	lower	intracellular	












Regulation	 of	 DNA	 methylation	 in	 the	 context	 of	 adenosine	 levels	 may	 be	 an	 important	














and	 counter	 the	 over-expression	 of	 ADK	 (Liou	 et	 al.,	 2008).	 However,	 this	 could	 also	 block	
adenosine	transport	into	other	cell	types,	which	would	be	deficient	in	adenosine	in	this	scenario.	
Therefore,	 future	 research	 must	 focus	 on	 the	 in	 vivo	 effects	 of	 cannabinoid	 treatment	 for	










































































































following	CBG	or	 CBD	 treatment	 in	wild	 type	D.	 discoideum,	MEFs	 and	PBMCs	 from	healthy	
controls	 (Figure	 7.2	 A	 ii).	 In	 IPMK	 over-expressing	D.	 discoideum	 cells	 (dIPMK+	 and	 hIPMK+),	
elevated	IPMK	expressions	leads	to	IPMK	becoming	a	major	source	of	PIP3	production	elevating	
mTORC1	 activity	 through	 PKB	 signalling	 (Figure	 7.2	 B	 i).	 In	 this	 case,	 when	 CBG	 and	 CBD	




and	MEF	 cells	 following	pharmacological	 PI3K	 inhibition.	 In	 the	 absence	of	 PI3K	 activity,	 the	






PKBA	 could	 result	 in	 an	 elevated	 amount	 of	mTOR	 and	 LST8	 proteins	 available	 for	mTORC1	





not	 result	 in	elevation	of	mTORC1	activity	 (as	 in	PI3K	 inhibitor-treated	cells)	 (Figure	7.2	F	 ii).	
These	proposed	mechanisms	require	further	exploration	to	verify.	Furthermore,	experiments	in	
mammalian	cells	are	necessary	 to	confirm	the	whole	mechanism	 is	conserved.	However,	 the	
































































































































































































































































































and	 reduced	 mTORC1	 signalling	 in	 neurons	 due	 to	 pro-inflammatory	 cytokines	 released	 by	





could	 support	 myelin	 repair	 in	 MS	 due	 to	 the	 proposed	 stabilisation	 of	 IPMK/mTORC1	 in	
activated	cells.	
To	 determine	 the	 ability	 of	 cannabinoids	 to	 treat	MS,	 experimental	 procedures	 examining	 a	
reduction	in	disease-related	symptoms	are	necessary.	One	such	example	would	be	to	examine	
if	myelin	degradation	on	neurons	is	altered	by	cannabinoid	treatment	(Goebbels	et	al.,	2017).	In	
model	 mice,	 ablation	 of	 PTEN	 which	 catalyses	 the	 production	 of	 PIP2	 from	 PIP3	 resulted	 in	




spasticity	 associated	 with	 MS	 (Arévalo-Martín	 et	 al.,	 2003).	 Remyelination,	 or	 blocking	 of	
immune	cell	degradation	of	myelin,	 is	a	key	aspect	of	any	MS	treatment.	Other	studies	have	











This	 study,	 along	 with	 previous	 studies,	 provides	 evidence	 of	 the	 necessity	 of	 personalised	
medicine.	The	PBMCs	from	patients	with	MS	displayed	elevated	mTORC1	activity,	which	was	
reduced	 by	 cannabinoid	 treatment,	whereas	 cannabinoid	 treatment	 of	 PBMCs	 from	 healthy	




























mTORC1	signalling,	the	 immune	cells	attack	myelin,	and	this	 results	 in	myelin	degradation	and	





an	 elevated	 mTORC1	 activity	 in	 immune	 cells).	 Other	 studies	 have	 indicated	 a	 therapeutic	
modulation	 of	mTOR	 activity	 to	 treat	MS	 is	 cell	 type-specific	 (Giacoppo	 et	 al.,	 2017).	 To	 be	
certain	 that	 cannabinoids	 can	 result	 in	 the	 treatment	of	MS	 in	 all	 cases	 analysis	 of	mTORC1	
activity	 for	 each	 patient	 before	 receiving	 treatment	 needs	 to	 be	 carried	 out.	 Alternatively,	
mTORC1	 activity	 in	 vivo	 could	 be	 analysed	 for	 different	 cell	 types	 in	 a	mouse	model	 of	MS	
(Giacoppo	et	al.,	2017).	Furthermore,	if	IPMK	over-expression	is	a	causative	factor	of	MS	and	the	
elevated	level	of	mTORC1	activity	in	PBMCs	from	patients	with	MS	observed	in	this	thesis,	then	





around	half	of	patients	 (Zettl	 et	 al.,	 2016).	 In	PBMCs	 from	healthy	 volunteers	CBG,	CBD	and	
THC:CBD	elevate	mTORC1	activity,	which	enhances	immune	cell	activation	and	could	exacerbate	
















The	amount	of	 PIP3	produced	by	 IPMK	 should	also	be	analysed	 in	D.	discoideum	using	mass	
spectrometry	(Kielkowska	et	al.,	2014).	This	could	be	carried	in	wild	type	cells	compared	to	IPMK	









of	 the	 different	 key	 components	 of	 IPMK	 one	 at	 a	 time	 until	 no	 longer	 possible	 could	 help	
determine	 this.	 This	 would	 then	 help	 to	 understand	 the	 essential	 role	 IPMK	 plays	 in	 most	
eukaryotes	(Saiardi	et	al.,	2018).	It	is	possible	that	the	combination	of	components	in	IPMK	is	




























indicates,	 cells	 could	 be	 treated	 with	 CBG	 in	 the	 presence	 of	 tritium-labelled	 adenosine	
([3H]adenosine)	(Carrier	et	al.,	2006).	Previous	studies	have	found	that	 in	blocking	adenosine	
transport	through	ENT1,	CBD	blocks	the	uptake	of	tritium-labelled	adenosine.	However,	when	
CBD	 blocks	 adenosine	 uptake,	 the	 intracellular	 content	 of	 adenosine	 does	 not	 change,	 and	

















compared	 to	 wild	 type,	 whether	 CBG	 activates	 mTORC1	 in	 wild	 type,	 and	 whether	 CBG	
downregulates	 mTORC1	 in	 IPMK	 overexpressing	 cells.	 If	 this	 is	 the	 case	 in	 cell	 lines,	 then	
experiments	can	be	carried	forward	to	 in	vivo.	Remyelination	assays	in	a	complex	cell	culture	
















CBG	 treatment,	 as	 occurs	 in	wild	 type	D.	 discoideum,	 then	 this	 could	 indicate	 the	 potential	

















2016)	 and	 cancer	 (Alayev	 and	Holz,	 2013),	 it	would	 be	 essential	 to	 determine	whether	 CBG	
treatment	 can	 increase	 the	 risk	of	 this	 in	healthy	 individuals	 and	whether	CBG	 treatment	of	





could	 be	 beneficial	 for	 the	 treatment	 of	 epilepsy,	 as	 astrocytes	 store	 a	 large	 amount	 of	
adenosine	as	AMP,	ADP	and	ATP	(Diógenes	et	al.,	2014).	If	CBG	prevented	the	accumulation	of	
adenosine	in	astrocytes	then,	this	could	be	beneficial.	However,	if	CBG	prevents	the	uptake	of	










the	 brain	 of	 epilepsy	 mouse	 models	 and	 wild	 type	 mice.	 If	 CBG	 treatment	 increases	 DNA	
methylation	in	both	mice	types,	it	may	be	worth	evaluating	the	risk	of	long	term	CBG	treatment.	








24	million	 people)	 (Adams	 et	 al.,	 2005;	 Purcell	 et	 al.,	 2009).	Most	 schizophrenia	 treatments	
involve	the	use	of	dopaminergic	receptor	inhibition,	which	reduces	the	likelihood	and	threshold	
of	 action	 potentials	 in	 neurons,	 and	 therefore	 reduces	 the	 misfiring	 and	 spread	 of	 action	
potentials	 that	 occurs	 during	 schizophrenia	 (Renard	 et	 al.,	 2016).	 In	 amphetamine-induced	
schizophrenic	 rats,	CBD	 injected	directly	 into	 the	nucleus	accumbens	shell	 (a	common	target	

















ameliorate	 schizophrenia-	 and	 psychosis-related	 symptoms,	 while	 THC	 may	 cause	 these	
symptoms.		
Interestingly,	 the	 amphetamine-induced	 mouse	 model	 of	 schizophrenia	 had	 reduced	 mTOR	








to	elevate	mTOR	signalling	 in	 this	 thesis	 in	wild	 type	D.	discoideum,	mouse	 cells	 and	human	
PBMCs,	 this	 suggests	a	potential	 shared	mechanism	and	a	potential	 therapeutic	use	 for	CBG	
along	with	CBD	in	treating	schizophrenia.		
There	is	also	a	theory	that	schizophrenia	develops	or	worsens	in	a	similar	way	to	epilepsy.	That	
is,	 over-expression	 of	 ADK	 (specifically	 in	 astrocytes	 and	 similar	 adenosine	 sinks)	 can	 cause	
schizophrenia	and	that	augmentation	of	adenosine	can	treat	the	disease	or	improve	symptoms	
(Shen	et	al.,	2012).	If	this	is	the	case,	then	CBG	may	have	a	similar	effect	as	it	would	on	epilepsy	




The	 therapeutic	 potential	 of	 cannabinoids	 for	 cancer	 treatment	 has	 also	 been	 explored	 in	
multiple	models	of	cancer	pathologies.	In	a	mouse	model	of	breast	cancer,	CBD	was	found	to	
have	 a	 low-toxicity	 profile	 and	 inhibited	 the	 proliferative	 and	 invasive	 phenotype	 of	 breast	
cancer	cells	(McAllister	et	al.,	2007).	Using	a	mouse	mammary	tumour	cell	line	implanted	into	
mice,	CBD	reduced	the	metastasis	of	cancer	cells	and	cell	proliferation,	potentially	through	an	






be	 further	 explored	 as	 a	 potential	 treatment	 of	 cancer,	 given	 the	 effects	 of	 CBG	 on	 cell	
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M6250),	5x	 loading	buffer	 (Bioline,	BIO-37045),	absorbent	 filter	pads	 (Millipore,	AP1004700),	
agarose	 (Bioline,	 B10-41026),	 Ampicillin	 (Sigma-Aldrich,	 A1593),	 blasticidin	 (Apollo	 Scientific,	
BIB4432),	 bromophenol	 blue	 (Sigma-Aldrich,	 B0126),	 DMSO	 (VWR,	 VWRV0231),	 Dulbecco's	
Modified	Eagle	Medium	(DMEM)	(Sigma-Aldrich,	D0819),	ethidium	bromide	(Bio-Rad,	1610433),	
Ethylenediaminetetraacetic	 acid	 (EDTA)	 (Sigma-Aldrich,	 E9884),	 fetal	 bovine	 serum	 (FBS)	
(ThermoFisher,	26140087),	G418	(PAA	laboratories,	11558616),	glucose	(Sigma-Aldrich,	G8270),	
HCl	(VWR,	20252),	glycerol	(Sigma-Aldrich,	G5516),	HEPES	(Sigma-Aldrich,	H3375),	HL5	media	
(ForMedium,	 HLB0103),	 Horse	 serum	 (Sigma-Aldrich,	 H0146-5ML),	 K2CO3	 (Sigma-Aldrich,	
P5833),	K2HPO4	 (Sigma-Aldrich,	1551128),	KCl	 (Sigma-Aldrich,	P9333),	KH2PO4	 (Sigma-Aldrich,	
NIST200B),	LY294002	(Cambridge	Bioscience,	CAY70920),Lymphoprep™	(Axis-Shield,	1114545),	
MgCl2	 (Sigma-Aldrich,	 M8266),	 MgSO4	 (Sigma-Aldrich,	 M7506),	 NaCl	 (Sigma-Aldrich,	 S9888),	
NaH2PO4	(Sigma-Aldrich,	S8282),	NaHCO3	(Sigma-Aldrich,	S5761),	nitrocellulose	filter	(Millipore,	
HABP04700),	 nuclease-free	water	 (Sigma-Aldrich,	W4502),	 nonyl	 phenoxypolyethoxylethanol	
40	 (NP40)	 substitute	 (Sigma-Aldrich,	 74385),	 Odyssey	 chemifluorescent	 substrate	 kit	
chemifluorescent	 substrate	 (Li-Cor,	 928-30005),	 OrangeG	 (Sigma-Aldrich,	 penicillin	 and	
streptomycin	 (Thermo	 Fisher	 Scientific,	 15140122),	 perchloric	 acid	 (Sigma-Aldrich,	 311421),	
Pictilisib	(AbCam,	ab141352),	protease	inhibitor	(ThermoFisher,	87786),	phosphatase	Inhibitor	
Cocktail	 2	 (Sigma-Aldrich,	 P5726),	 phosphatase	 Inhibitor	 Cocktail	 3	 (Sigma-Aldrich,	 P0044),	
plates	(Corning,	353801),	proteinase	K	(Fermentas,	EO0491),	radioimmunoprecipitation	assay	
(RIPA)	buffer	(ThermoFisher,	89900),	SM	agar	(ForMedium,	SMA0102),	sodium	acetate	(Sigma-
Aldrich,	 S2889),	 sodium	 dodecyl	 sulfate	 (SDS)	 solution	 (Sigma-Aldrich,	 L3771),	 tissue	 culture	
flasks	 (Corning®	 CellBIND®	 Surface	 cell	 culture	 flasks,	 Sigma-Aldrich,	 CLS3289)	 Tris	 acetate	
ethylenediaminetetraacetic	acid	(EDTA)	(TAE)	buffer	(Severn	Biotech	Limited,	20-6001-50),	Tris	
buffer	saline	(TBS)	(Fisher,	10776834),	Trizma	(Tris)-HCl	pH	8.3	(Sigma-Aldrich,	T1503),	Trypsin	





Cannabigerol	 (CBG),	 cannabidiol	 (CBD),	 cannabidivarin	 (CBDV),	 cannabidiolic	acid	 (CBDA)	and	
THC:CBD	combinations	(20	nM:17	nM)	were	provided	by	GW	pharmaceuticals,	England.	Stock	
concentrations	of	these	were	100	mM.	Cannabinoids	were	dissolved	in	DMSO	(except	for	use	










GoTaq®	G2	Flexi	DNA	Polymerase	 (Promega,	M7801),	Q5	high	 fidelity	DNA	polymerase	 (New	
England	Biolabs,	M0491),	T4	DNA	ligase	(Fermentas,	15224041).	
9.1.6	Antibodies	
Anti-phospho-4EBP1	 (rabbit,	 Cell	 Signalling	 Technology,	 9459),	 anti-total	 4EBP1	 (rabbit,	NEB,	
4923),	anti-actin	(mouse,	Sigma-Aldrich,	A1978),	anti-IPMK	antibody	(ab96753),	anti-RFP	(rat,	
Chromotek,	5F8),	Streptavidin	(Alexa	Fluor™	680	conjugate,	Thermo	Fisher,	S21378),	Anti-rabbit	
immunoglobulins	 (goat,	 Horseradish	 peroxidase	 (HRP),	 Agilent	 Technologies,	 P0448),	 Anti-




A1120),	 QIAquick®	 PCR	 purification	 kit	 (Qiagen,	 28104),	 TOPO	 TA	 Cloning®	 kit	 (Invitrogen,	
K450002),	 Plasmid	mini-prep	kit	 (Qiagen,	27104),	HiSpeed	Plasmid	Maxi	Kit	 (Qiagen,	12643),	
189	
	
RNeasy	mini-kit	 (Qiagen,	 74104),	 First-strand	 cDNA	 synthesis	 kit	 (Thermo	 Scientific,	 K1612),	







Table	9.1:	Primer	 sequences,	name,	 function	 and	 restriction	enzyme	 cut	 sites.	All	primers	used	 in	 this	 thesis	 are	
contained	within	this	table. 












































11 Ig7F RT-PCR	for	Ig7	control GTACTGTGAAGGAAAGATGAAAAG




14 p10 Inverse	PCR	of	mutant	library GTAGAAGTAGCGACAGAGAAG






















21 IPMK	OE	5’	forward Production	of	dIPMK over-
expressor	plasmid
ATAAGATCTATGTCATCATCATCACTTA BglII

































29 IhPMK OE	5’	forward Production	of	hIPMK over-
expressor	plasmid
AGATCTATGGCAACAGAACC BglII












quadrupole	 mass	 spectrometer	 (Shimadzu	 Corp.,	 Japan).	 NanoDrop	 ND-1000	


























WT	(AX3)	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
1.6	 1.6	 2.7	 1.7	 5.1	 	 10.0	 3.9	 2.9	 0.9	 1.5	 	 3.18	 2.56	
6.9	 8.3	 9.3	 8.9	 37.2	 10.4	 47.1	 18.3	 9.6	 2.0	 12.0	 	 15.44	 13.27	
28.5	 27.9	 40.5	 43.6	 74.5	 56.7	 89.4	 114.5	 32.5	 8.5	 24.8	 	 49.21	 30.30	
66.1	 78.2	 111.0	 96.4	 80.7	 92.2	 104.2	 127.5	 90.4	 51.5	 70.2	 	 88.05	 20.72	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
	 	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
	 	 2.4	 1.3	 6.3	 	 8.5	 4.3	 1.9	 0.6	 1.5	 	 3.33	 2.60	
	 	 9.2	 7.7	 31.7	 11.0	 44.7	 16.8	 9.2	 1.1	 9.8	 	 15.67	 13.00	
	 	 32.3	 32.1	 74.3	 54.2	 82.4	 121.7	 27.7	 2.1	 23.8	 	 50.08	 34.82	
	 	 93.0	 97.8	 78.3	 83.9	 97.2	 121.7	 80.7	 4.7	 67.9	 	 80.58	 30.46	
	 	 86.0	 120.1	 87.9	 98.8	 94.1	 108.7	 103.6	 25.3	 95.2	 	 91.08	 25.30	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
0.9	 1.2	 1.7	 1.7	 3.8	 	 5.4	 2.2	 0.9	 0.2	 1.5	 	 1.94	 1.47	
3.8	 3.3	 6.7	 6.4	 18.0	 10.2	 23.0	 11.9	 3.2	 0.2	 4.4	 	 8.28	 6.63	
20.7	 14.9	 19.3	 28.5	 54.1	 35.6	 87.1	 34.8	 9.4	 0.6	 22.9	 	 29.80	 22.69	
16.5	 34.7	 91.0	 97.8	 77.8	 64.1	 81.2	 113.0	 37.3	 1.1	 51.2	 	 60.51	 33.82	
67.2	 69.2	 92.0	 118.7	 67.7	 81.1	 82.4	 121.7	 79.5	 3.9	 95.2	 	 79.89	 29.91	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.1	 	 0.10	 0.01	
0.4	 0.3	 0.4	 0.7	 0.6	 	 0.8	 1.4	 0.6	 	 0.3	 	 0.61	 0.33	
0.9	 1.1	 1.8	 2.4	 3.4	 2.4	 5.0	 4.3	 2.7	 	 2.2	 	 2.63	 1.25	
2.3	 2.3	 2.8	 11.8	 13.5	 9.2	 16.9	 14.5	 4.6	 	 2.1	 	 7.98	 5.54	
7.5	 9.3	 15.5	 39.9	 36.4	 43.7	 63.5	 46.4	 16.9	 	 9.0	 	 28.81	 18.61	
24.1	 20.7	 47.8	 99.2	 61.6	 70.0	 82.4	 72.5	 55.4	 	 32.8	 	 56.63	 24.34	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.09	 0.02	
0.3	 0.1	 0.2	 0.1	 0.2	 	 0.4	 0.3	 0.3	 0.0	 0.3	 	 0.21	 0.11	
0.3	 0.4	 0.4	 0.1	 0.1	 0.2	 0.5	 1.1	 1.0	 0.1	 0.7	 	 0.43	 0.34	
1.0	 0.8	 0.6	 0.2	 0.6	 0.3	 1.1	 0.9	 2.9	 0.1	 0.6	 	 0.82	 0.73	
2.3	 1.9	 2.8	 0.7	 1.1	 1.2	 3.0	 	 12.0	 0.3	 1.7	 	 2.70	 3.22	
6.9	 5.7	 6.5	 1.5	 1.8	 5.1	 10.6	 	 30.4	 0.6	 1.7	 	 7.07	 8.31	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 	 0.1	 	 0.10	 0.01	
0.0	 0.0	 0.0	 0.0	 	 0.0	 0.0	 0.1	 0.2	 	 0.1	 	 0.05	 0.06	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 	 0.1	 	 0.03	 0.04	
0.0	 0.0	 0.1	 0.1	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.1	 	 0.03	 0.04	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.2	 	 0.04	 0.07	









ENT1-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
2.3	 1.8	 3.8	 2.2	 4.5	 	 5.4	 1.8	 	 3.11	 1.35	
9.7	 10.6	 11.6	 8.6	 27.1	 15.6	 26.0	 8.7	 	 14.74	 7.13	
32.6	 27.9	 48.6	 38.6	 55.3	 63.0	 51.9	 24.2	 	 42.76	 13.08	
75.2	 64.3	 100.0	 85.8	 69.1	 130.2	 100.0	 78.9	 	 87.95	 20.12	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
	 	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.11	 0.05	
	 	 4.9	 2.0	 4.7	 	 6.5	 2.1	 	 4.05	 1.75	
	 	 18.0	 7.4	 17.6	 20.2	 23.4	 7.4	 	 15.68	 6.14	
	 	 72.2	 22.1	 53.4	 71.7	 54.5	 23.7	 	 49.61	 20.27	
	 	 117.8	 73.7	 92.1	 106.8	 102.6	 76.3	 	 94.89	 15.95	
	 	 88.9	 104.3	 131.6	 100.0	 103.9	 113.2	 	 106.96	 13.14	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
2.1	 1.4	 4.1	 1.7	 2.9	 	 4.7	 2.0	 	 2.72	 1.16	
5.1	 5.5	 9.9	 3.0	 28.4	 22.4	 14.0	 5.3	 	 11.71	 8.68	
22.2	 17.2	 43.6	 12.1	 27.6	 72.1	 42.9	 16.4	 	 31.76	 18.80	
61.0	 47.2	 108.9	 40.3	 66.8	 134.0	 87.0	 76.3	 	 77.69	 29.50	
113.0	 77.1	 91.1	 93.3	 84.2	 109.4	 102.6	 89.5	 	 95.03	 11.59	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.6	 0.6	 1.9	 1.0	 1.0	 	 2.9	 1.6	 	 1.38	 0.76	
4.7	 1.7	 5.5	 1.3	 2.3	 7.5	 14.0	 5.3	 	 5.29	 3.86	
13.2	 6.3	 11.4	 4.9	 4.6	 22.2	 35.1	 15.8	 	 14.19	 9.69	
39.6	 27.6	 41.1	 12.8	 15.9	 77.3	 71.4	 47.4	 	 41.63	 22.06	
75.3	 49.5	 104.4	 47.6	 36.8	 133.1	 106.5	 73.7	 	 78.38	 31.62	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.2	 0.3	 0.6	 0.2	 0.3	 	 2.9	 1.4	 	 0.83	 0.92	
1.0	 0.8	 1.5	 0.2	 0.3	 0.9	 7.0	 2.5	 	 1.79	 2.09	
1.9	 1.4	 4.1	 0.2	 0.7	 2.9	 10.1	 9.5	 	 3.85	 3.62	
4.7	 3.3	 11.1	 0.4	 2.0	 5.7	 53.2	 21.1	 	 12.69	 16.52	
18.5	 9.2	 21.9	 0.8	 5.3	 8.9	 68.8	 52.6	 	 23.25	 22.90	
	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.1	 0.1	 0.1	 0.1	 0.1	 0.1	 0.2	 	 0.09	 0.06	
0.1	 0.0	 0.0	 0.1	 0.0	 	 0.3	 0.2	 	 0.10	 0.11	
194	
	
0.0	 0.0	 0.2	 0.1	 0.0	 0.0	 0.8	 0.3	 	 0.18	 0.27	
0.1	 0.0	 0.2	 0.1	 0.0	 0.0	 1.0	 0.4	 	 0.23	 0.33	
0.0	 0.1	 0.0	 0.0	 0.1	 0.0	 1.4	 1.3	 	 0.35	 0.56	






WT	(AX2)	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
7.6	 9.7	 11.2	 	 2.8	 2.0	 1.5	 	 5.80	 3.85	
15.8	 23.2	 22.9	 11.9	 5.4	 6.4	 12.0	 	 13.93	 6.64	
24.7	 34.8	 37.6	 22.2	 8.0	 30.8	 24.8	 	 26.13	 9.08	
57.0	 74.9	 54.1	 54.8	 54.5	 69.0	 70.2	 	 62.07	 8.27	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
8.2	 7.7	 8.2	 	 3.7	 1.8	 1.5	 	 5.20	 2.95	
12.7	 15.5	 21.8	 10.4	 4.8	 4.2	 9.8	 	 11.30	 5.65	
20.9	 30.0	 40.0	 18.5	 5.7	 23.5	 23.8	 	 23.20	 9.71	
39.9	 69.1	 84.1	 74.1	 40.8	 56.3	 67.9	 	 61.73	 15.54	
57.6	 81.2	 148.8	 139.3	 79.5	 60.5	 95.2	 	 94.59	 33.54	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
7.0	 8.7	 6.5	 	 2.6	 1.7	 1.5	 	 4.67	 2.81	
10.8	 16.4	 22.4	 9.6	 4.4	 3.9	 4.4	 	 10.26	 6.49	
19.6	 23.2	 45.9	 26.7	 5.3	 18.1	 22.9	 	 23.08	 11.26	
28.5	 53.6	 63.5	 68.1	 19.4	 56.3	 51.2	 	 48.67	 16.71	
43.0	 89.9	 107.6	 135.6	 52.2	 54.5	 95.2	 	 82.57	 31.45	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 	 	 0.1	 	 0.34	 0.39	
4.4	 6.3	 5.3	 	 	 	 0.3	 	 4.07	 2.28	
10.1	 13.0	 11.2	 9.6	 	 	 2.2	 	 9.23	 3.71	
10.8	 22.2	 37.1	 7.4	 	 	 2.1	 	 15.91	 12.46	
18.4	 46.4	 54.7	 36.3	 	 	 9.0	 	 32.96	 17.02	
56.3	 71.0	 77.1	 63.0	 	 	 32.8	 	 60.03	 15.34	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
1.9	 4.3	 4.7	 	 1.3	 1.2	 0.3	 	 2.29	 1.65	
2.5	 5.3	 13.5	 2.2	 2.1	 2.0	 0.7	 	 4.06	 4.07	
1.3	 10.1	 14.1	 2.2	 2.9	 10.8	 0.6	 	 6.00	 5.09	
2.5	 13.5	 23.5	 7.4	 9.4	 14.4	 1.7	 	 10.35	 7.04	
7.0	 19.8	 45.3	 17.8	 22.6	 25.3	 1.7	 	 19.93	 13.01	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.6	 1.0	 0.0	 0.0	 0.0	 0.0	 0.1	 	 0.24	 0.37	
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0.0	 0.0	 4.1	 	 0.4	 0.0	 0.1	 	 0.76	 1.51	
0.0	 0.5	 11.8	 0.0	 0.4	 0.2	 0.1	 	 1.85	 4.05	
0.6	 0.0	 3.5	 0.0	 0.4	 0.3	 0.1	 	 0.71	 1.17	
0.0	 1.0	 6.5	 1.5	 2.6	 0.4	 0.2	 	 1.73	 2.09	
1.9	 1.0	 28.8	 5.2	 5.3	 0.5	 0.3	 	 6.14	 9.46	
	
DNMA-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 3.5	 	 3.1	 	 5.8	 2.0	 2.4	 	 3.37	 1.32	
12.8	 11.7	 9.4	 15.8	 8.4	 36.8	 12.6	 3.9	 7.0	 	 13.17	 9.00	
41.0	 60.5	 59.9	 42.8	 21.6	 123.1	 22.2	 11.6	 11.4	 	 43.80	 33.13	
112.6	 122.4	 100.0	 91.4	 91.5	 147.8	 59.3	 44.7	 65.3	 	 92.77	 30.80	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 2.4	 	 3.3	 	 7.0	 1.4	 2.4	 	 3.31	 1.92	
13.4	 16.5	 7.5	 12.9	 13.5	 14.4	 8.7	 3.5	 6.7	 	 10.79	 4.07	
50.5	 61.8	 33.2	 29.8	 25.0	 47.6	 18.5	 12.1	 9.8	 	 32.05	 17.00	
92.6	 110.5	 75.0	 110.4	 91.5	 160.1	 55.6	 51.3	 61.2	 	 89.79	 32.48	
124.2	 119.8	 133.4	 100.0	 119.2	 100.0	 103.7	 102.6	 97.9	 	 111.19	 12.28	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.0	 	 0.0	 0.1	 	 0.3	 0.1	 0.3	 	 0.12	 0.13	
	 	 	 	 	 	 4.3	 1.4	 2.4	 	 2.72	 1.19	
13.2	 13.3	 	 19.1	 104.3	 	 6.7	 3.9	 4.9	 	 23.62	 33.31	
45.2	 47.3	 	 31.1	 168.1	 	 15.6	 15.8	 13.1	 	 48.02	 50.77	
102.1	 122.4	 	 84.4	 187.3	 	 55.6	 59.2	 61.2	 	 96.02	 43.77	
83.1	 147.4	 	 115.6	 106.4	 	 107.4	 102.6	 91.8	 	 107.78	 18.98	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
	 	 	 	 	 	 0.3	 0.1	 0.3	 	 0.24	 0.10	
	 	 	 	 	 	 1.6	 3.2	 2.6	 	 2.47	 0.63	
	 	 	 	 	 	 6.1	 4.7	 5.9	 	 5.56	 0.59	
	 	 	 	 	 	 13.3	 6.3	 11.4	 	 10.36	 2.96	
	 	 	 	 	 	 32.6	 34.2	 40.8	 	 35.86	 3.54	
	 	 	 	 	 	 74.1	 69.7	 81.6	 	 75.13	 4.89	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
	 	 2.1	 	 3.3	 	 2.5	 2.1	 2.0	 	 2.38	 0.51	
12.3	 10.2	 5.1	 10.0	 6.8	 12.2	 3.6	 4.2	 2.4	 	 7.43	 3.61	
33.6	 35.5	 16.9	 25.9	 18.2	 19.9	 11.1	 10.8	 9.0	 	 20.10	 9.18	
100.0	 77.6	 36.6	 61.0	 76.6	 84.6	 13.3	 30.3	 28.5	 	 56.50	 28.44	
80.0	 136.9	 83.3	 79.2	 122.4	 123.1	 30.4	 77.6	 61.2	 	 88.23	 31.83	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
	 	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.12	 0.13	
	 	 1.7	 	 2.3	 	 1.6	 1.8	 2.4	 	 1.98	 0.33	
	 	 4.4	 4.7	 4.1	 7.3	 1.9	 3.2	 3.1	 	 4.09	 1.56	
	 	 10.9	 16.8	 8.0	 12.8	 7.4	 4.3	 5.7	 	 9.41	 4.04	
	 	 26.6	 23.6	 20.4	 41.5	 8.1	 14.5	 24.5	 	 22.72	 9.68	
	 	 106.7	 61.7	 42.5	 76.9	 9.6	 30.3	 28.5	 	 50.88	 30.71	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
	 	 0.0	 0.0	 0.1	 0.0	 0.1	 	 	 	 0.04	 0.05	
	 	 2.4	 	 1.6	 	 0.9	 	 	 	 1.64	 0.62	
	 	 5.1	 6.1	 2.0	 4.5	 3.2	 	 	 	 4.16	 1.46	
	 	 11.5	 20.7	 3.2	 11.0	 3.5	 	 	 	 9.97	 6.44	
	 	 33.2	 33.7	 4.1	 21.4	 6.8	 	 	 	 19.86	 12.58	
	 	 78.3	 68.8	 11.4	 36.8	 17.6	 	 	 	 42.60	 26.80	
	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
196	
	
0.0	 0.0	 0.0	 0.0	 0.1	 0.0	 0.3	 0.1	 0.3	 	 0.09	 0.12	
0.5	 0.2	 0.9	 	 0.0	 	 0.3	 0.5	 1.5	 	 0.56	 0.47	
0.0	 0.0	 1.4	 8.2	 1.6	 1.7	 0.3	 2.1	 1.8	 	 1.91	 2.36	
0.0	 0.0	 2.6	 22.0	 7.2	 6.0	 6.4	 2.3	 2.0	 	 5.38	 6.39	
0.0	 0.0	 13.6	 48.0	 3.9	 16.8	 7.6	 7.9	 6.5	 	 11.58	 13.90	
0.1	 0.2	 18.6	 68.8	 7.6	 30.7	 7.9	 23.2	 8.3	 	 18.37	 20.30	
	
	
IPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.8	 4.6	 4.8	 7.1	 2.5	 4.2	 	 4.17	 1.72	
6.7	 25.0	 14.8	 20.0	 29.2	 33.6	 	 21.55	 8.99	
21.9	 65.0	 86.9	 51.3	 66.6	 78.3	 	 61.67	 20.99	
57.2	 77.0	 111.6	 117.2	 90.0	 96.7	 	 91.60	 20.33	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.3	 3.2	 6.0	 2.4	 2.2	 4.1	 	 3.19	 1.52	
2.9	 24.2	 22.4	 11.9	 29.6	 33.9	 	 20.81	 10.52	
19.1	 44.0	 65.2	 35.9	 70.0	 81.6	 	 52.63	 21.52	
57.2	 78.0	 105.8	 104.7	 91.7	 101.7	 	 89.83	 17.44	
96.9	 80.0	 100.0	 134.4	 101.7	 103.3	 	 102.71	 16.13	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
1.9	 3.9	 3.8	 4.1	 2.3	 2.7	 	 3.11	 0.87	
3.4	 23.2	 14.3	 22.5	 29.2	 33.6	 	 21.05	 9.88	
15.3	 58.0	 86.9	 38.1	 73.3	 78.3	 	 58.33	 24.84	
45.0	 61.0	 116.0	 112.5	 92.0	 86.6	 	 85.51	 25.63	
106.3	 70.0	 89.8	 109.4	 100.0	 87.3	 	 93.80	 13.29	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.5	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.9	 2.2	 1.3	 1.4	 2.3	 3.8	 	 2.00	 0.95	
2.8	 6.8	 2.3	 4.9	 29.6	 31.9	 	 13.04	 12.62	
11.8	 18.0	 10.7	 11.9	 73.3	 58.3	 	 30.66	 25.33	
35.3	 62.0	 40.5	 43.8	 90.0	 86.6	 	 59.71	 21.85	
79.7	 120.0	 66.6	 104.7	 100.0	 86.6	 	 92.95	 17.45	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.9	 0.3	 0.9	 0.3	 0.5	 0.3	 	 0.55	 0.28	
2.2	 1.4	 1.2	 1.9	 1.1	 3.1	 	 1.84	 0.69	
7.7	 2.4	 3.7	 4.1	 1.9	 5.3	 	 4.19	 1.91	
27.5	 5.3	 10.7	 14.4	 2.3	 6.6	 	 11.13	 8.27	
86.8	 13.8	 23.4	 35.9	 5.5	 12.2	 	 29.61	 27.31	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.1	 0.1	 0.1	 0.1	 0.0	 0.0	 	 0.06	 0.05	
0.1	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.01	 0.02	
0.2	 0.1	 0.0	 0.1	 0.0	 0.1	 	 0.08	 0.07	
0.0	 0.1	 0.0	 0.1	 0.1	 0.6	 	 0.14	 0.21	
0.1	 0.0	 0.0	 0.1	 1.1	 0.9	 	 0.37	 0.47	








PKBA-	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
4.1	 	 	 	 3.8	 	 	 	 3.99	 0.15	
20.0	 20.6	 24.3	 6.7	 22.3	 23.0	 5.6	 	 17.50	 7.31	
93.0	 64.1	 70.0	 18.0	 80.0	 92.6	 14.5	 	 61.73	 30.42	
128.1	 149.1	 114.0	 81.8	 96.0	 115.4	 93.3	 	 111.10	 21.27	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
5.6	 	 	 	 4.4	 	 	 	 5.01	 0.60	
25.3	 14.2	 23.9	 15.6	 17.9	 16.8	 6.7	 	 17.19	 5.77	
93.0	 79.2	 74.5	 90.9	 78.0	 92.3	 15.7	 	 74.79	 25.13	
124.6	 151.0	 138.0	 242.7704*	 94.0	 110.8	 249.1541*	 123.68	 20.01	
110.5	 118.9	 100.0	 215.4	 80.0	 100.0	 125.8	 	 121.52	 40.74	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
3.6	 	 	 	 3.1	 	 	 	 3.35	 0.23	
17.9	 11.9	 24.7	 35.0	 13.9	 18.4	 7.0	 	 18.40	 8.51	
47.7	 51.9	 68.0	 145.6	 74.0	 90.8	 18.1	 	 70.84	 37.18	
140.4	 107.6	 114.0	 218.469*	 144.1	 124.6	 302.5824*	 126.13	 14.27	
112.3	 156.7	 112.0	 227.6	 134.1	 101.5	 135.6	 	 139.97	 39.70	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
0.7	 	 	 	 3.0	 	 	 	 1.83	 1.13	
4.6	 8.4	 10.7	 14.9	 15.5	 12.2	 3.7	 	 9.99	 4.35	
11.8	 37.6	 37.0	 42.3	 86.0	 89.2	 7.4	 	 44.47	 29.94	
122.8	 126.5	 100.0	 218.469*	 106.0	 112.3	 43.0	 	 101.77	 27.80	
138.6	 134.0	 138.0	 218.5	 154.1	 92.3	 115.6	 	 141.58	 36.35	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
	 	 	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 2.3	 	 	 	 2.32	 0.00	
	 	 	 4.1	 5.4	 27.9	 1.8	 	 9.82	 10.53	
	 	 	 18.6	 9.9	 75.4	 2.7	 	 26.62	 28.70	
	 	 	 91.5	 59.1	 140.0	 22.1	 	 78.19	 43.34	
	 	 	 154.7	 63.9	 100.0	 44.3	 	 90.74	 41.97	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
	 	 	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.4	 	 	 	 1.44	 0.00	
	 	 	 3.5	 1.3	 8.2	 0.8	 	 3.45	 2.93	
	 	 	 8.9	 1.8	 21.1	 0.9	 	 8.16	 8.10	
	 	 	 2.8	 2.5	 118.5	 1.1	 	 31.21	 50.39	
	 	 	 8.9	 3.8	 107.7	 5.6	 	 31.51	 44.03	
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4	µM	CBG	 	 	 	
0.1	 0.0	 0.1	 0.0	 0.0	 0.0	 0.0	 	 0.03	 0.05	
0.1	 0.0	 0.0	 	 1.0	 	 	 	 0.26	 0.41	
0.0	 0.0	 0.1	 5.0	 0.7	 4.2	 0.7	 	 1.53	 1.97	
0.1	 0.2	 0.1	 14.9	 0.6	 8.2	 0.8	 	 3.55	 5.39	
0.1	 1.3	 0.1	 9.5	 0.8	 39.6	 0.8	 	 7.45	 13.49	
0.1	 4.1	 0.2	 20.4	 5.8	 107.7	 1.2	 	 19.92	 36.43	
	
PKBA-IPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.2	 	 	 	 	 2.3	 	 1.28	 1.06	
2.6	 2.9	 16.5	 3.0	 1.9	 20.7	 	 7.93	 7.64	
9.8	 13.8	 73.3	 18.5	 3.2	 42.8	 	 26.90	 24.15	
57.8	 71.3	 102.2	 49.9	 27.9	 81.2	 	 65.05	 23.61	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
1.2	 	 	 	 	 2.4	 	 1.78	 0.62	
3.7	 4.9	 13.0	 3.3	 1.9	 19.4	 	 7.69	 6.35	
9.8	 21.8	 48.8	 20.4	 3.2	 38.9	 	 23.82	 15.75	
60.4	 157.3	 120.0	 84.3	 25.9	 83.5	 	 88.58	 41.79	
113.2	 228.9	 131.2	 103.1	 94.0	 101.3	 	 128.62	 46.38	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
3.8	 	 	 	 	 2.1	 	 2.94	 0.86	
4.9	 4.0	 12.3	 4.1	 0.8	 19.4	 	 7.58	 6.32	
16.1	 6.3	 31.0	 15.4	 8.7	 36.3	 	 18.97	 11.05	
81.5	 24.9	 75.5	 43.6	 30.7	 81.8	 	 56.35	 24.01	
155.4	 200.3	 95.5	 84.3	 67.9	 98.7	 	 117.03	 45.97	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
2.2	 	 	 	 	 2.3	 	 2.25	 0.04	
5.6	 2.0	 11.6	 2.9	 3.4	 20.7	 	 7.69	 6.62	
13.5	 5.4	 32.1	 6.3	 11.5	 45.4	 	 19.04	 14.73	
100.0	 10.9	 64.4	 24.8	 57.9	 77.9	 	 55.99	 30.27	
150.1	 164.4699*	 115.6	 59.3	 102.0	 97.4	 	 104.87	 29.34	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
1.2	 	 	 	 	 2.0	 	 1.59	 0.43	
1.5	 2.3	 3.4	 2.0	 1.8	 3.3	 	 2.38	 0.71	
1.6	 4.0	 10.1	 3.8	 2.7	 14.7	 	 6.14	 4.68	
2.1	 7.7	 31.9	 8.5	 12.7	 71.4	 	 22.38	 23.82	
6.1	 22.6	 88.9	 19.2	 59.9	 88.3	 	 47.51	 33.33	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.7	 	 	 	 	 0.5	 	 0.60	 0.14	
0.7	 0.6	 0.8	 1.1	 0.9	 0.5	 	 0.77	 0.20	
0.6	 1.1	 2.4	 1.1	 1.0	 7.2	 	 2.24	 2.27	
1.8	 1.4	 6.1	 1.5	 3.8	 11.0	 	 4.27	 3.42	
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3.0	 5.4	 7.8	 4.1	 10.3	 37.6	 	 11.37	 11.97	
	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.3	 0.0	 0.0	 0.0	 0.0	 	 0.05	 0.11	
0.5	 	 	 	 	 0.1	 	 0.32	 0.21	
0.9	 0.0	 0.1	 0.3	 0.6	 0.1	 	 0.34	 0.34	
0.8	 1.4	 0.7	 0.1	 1.0	 0.1	 	 0.70	 0.47	
0.7	 1.7	 3.4	 1.6	 1.8	 1.0	 	 1.72	 0.85	
1.6	 3.7	 3.8	 4.8	 6.7	 1.1	 	 3.62	 1.86	
	
hIPMK+	 	 	 	
0	µM	CBG	 	 Mean	 SD	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.5	 1.1	 1.0	 	 1.22	 0.22	
9.7	 4.8	 7.2	 8.3	 3.8	 4.4	 3.7	 	 6.00	 2.21	
23.0	 18.7	 36.4	 50.8	 9.5	 26.5	 8.3	 	 24.73	 13.95	
92.6	 91.1	 104.8	 105.3	 27.9	 103.1	 37.8	 	 80.37	 30.62	
100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 100.0	 	 100.00	 0.00	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.02	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 2.3	 1.1	 0.8	 	 1.39	 0.67	
15.0	 4.7	 8.3	 13.2	 5.4	 4.6	 3.8	 	 7.87	 4.20	
36.3	 17.6	 38.0	 49.1	 12.3	 26.5	 8.6	 	 26.90	 13.82	
113.3	 88.6	 103.2	 105.3	 29.5	 100.0	 38.1	 	 82.56	 31.66	
109.1	 89.9	 103.2	 105.3	 104.0	 101.6	 98.3	 	 101.61	 5.70	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
0.1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.0	 1.4	 0.7	 	 1.07	 0.29	
8.0	 4.8	 8.4	 8.6	 5.8	 4.0	 3.8	 	 6.20	 1.96	
37.2	 18.1	 23.7	 38.5	 9.9	 23.3	 9.7	 	 22.92	 10.79	
73.5	 88.6	 103.2	 87.7	 29.9	 95.0	 38.1	 	 73.70	 26.53	
107.0	 88.6	 101.6	 105.3	 108.0	 93.7	 95.4	 	 99.95	 6.90	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
1	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 1.4	 0.8	 1.1	 	 1.08	 0.22	
21.2	 4.1	 6.2	 12.5	 3.4	 3.0	 2.8	 	 7.61	 6.40	
64.6	 11.3	 17.4	 35.0	 4.2	 17.1	 8.3	 	 22.56	 19.44	
64.6	 49.3	 51.6	 57.8	 19.9	 33.0	 30.8	 	 43.86	 15.01	
175.2	 70.9	 58.7	 63.1	 63.9	 46.8	 42.0	 	 74.38	 42.21	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
2	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 0.2	 0.1	 0.3	 	 0.22	 0.07	
8.8	 2.4	 3.1	 2.3	 0.8	 0.5	 0.5	 	 2.64	 2.71	
9.7	 3.3	 2.7	 4.4	 1.4	 0.8	 0.7	 	 3.31	 2.91	
10.6	 6.2	 5.6	 8.5	 1.8	 1.1	 1.0	 	 4.99	 3.52	
15.9	 6.5	 6.9	 8.3	 3.2	 1.3	 1.0	 	 6.15	 4.78	
	 	 	 	 	 	 	 	 	 	
3	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 	 	 	 0.00	 0.00	
	 	 	 	 0.1	 	 	 	 0.08	 0.00	
1.8	 0.9	 2.0	 1.3	 0.1	 	 	 	 1.20	 0.69	
2.7	 1.0	 1.5	 1.5	 0.3	 	 	 	 1.38	 0.77	
5.3	 1.9	 2.9	 3.2	 1.4	 	 	 	 2.95	 1.34	
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7.1	 2.1	 3.8	 2.9	 1.5	 	 	 	 3.46	 1.96	
	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
4	µM	CBG	 	 	 	
0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 0.0	 	 0.00	 0.00	
	 	 	 	 0.2	 0.1	 0.1	 	 0.11	 0.04	
2.7	 1.4	 2.7	 0.9	 0.2	 0.5	 0.2	 	 1.22	 1.02	
3.5	 1.2	 2.7	 0.9	 0.2	 0.7	 0.3	 	 1.36	 1.19	
2.7	 2.5	 4.0	 1.8	 1.5	 1.0	 0.5	 	 2.00	 1.08	
8.0	 2.6	 4.2	 2.2	 1.8	 1.1	 0.6	 	 2.91	 2.33	
	
